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Fas (FasR, CD95, Apo-1) is a member of the tumour necrosis receptor superfamily 
and plays a crucial role in the induction of apoptosis. In addition, depending on the 
cell type, activation of Fas can also induce non-apoptotic signalling pathways, 
including inflammation and proliferation. Recently, we demonstrated that Fas-
deficient and adipocyte-specific Fas knockout mice are partly protected from insulin 
resistance induced by high-fat diet, but the mechanisms of this protective effect are 
incompletely understood. The aim of this study was to elucidate the molecular 
mechanisms behind this protective effect; in particular the impact of the Fas receptor 
on adipocyte metabolism. 
Incubation of differentiating 3T3-L1 preadipocytes with 2 ng/ml Fas ligand (FasL) 
reduced the early induction of the p44/42 MAP kinases (ERK1/2), which is important 
for the initiation of differentiation. Furthermore, activation of the Fas receptor led to a 
decreased expression of the adipogenic markers C/EBPα, C/EBPβ and PPARγ. 
Treatment with FasL also reduced C/EBPα and PPARγ in mature 3T3-L1 adipocytes. 
Moreover, activation of the Fas receptor in these cells influenced lipolysis in a time 
dependent fashion with an initial decrease after 2 hours and an approximately 2-fold 
increase after 12 hours. Fas activation induced phosphorylation of ERK1/2 with a 
peak after 6 hours and FasL-induced lipolysis was completely blocked by ERK1/2-
inhibition. Additionally, the thiazolidinedione rosiglitazone inhibited both Fas-induced 
ERK1/2 activation and lipolysis. 
We then aimed to determine upstream mediators and downstream effects of Fas-
induced ERK1/2 activation to dissect the pathway(s) leading to increased lipolysis. 
Fas activation reduced the PPARγ target perilipin. ERK1/2 dependent down-
regulation of perilipin was shown to increase lipolysis. However, Fas-induced 
reduction of this lipid droplet coating protein was independent of ERK1/2 activation. 
Furthermore, FasL treatment of adipocytes led to an increased secretion of the 
cytokines IL-6, KC (mouse IL-8 homologue) but not of TNFα. But neither IL-6 nor KC 
was found to be responsible for the ERK1/2-dependent induction of lipolysis. 
Fas induced ERK1/2 activation and lipolysis could be partly reduced using extra- and 
intracellular calcium chelators and an inhibitor of calcium/calmodulin dependent 
 II
Summary 
 III
protein kinase II (CaMKII). However, we failed to demonstrate an increase in the 
enzyme’s activity after FasL treatment. 
Interestingly, FasL treatment reduced mRNA-expression and protein levels of the 
C/EBPα  target lipin-1, a phosphatase involved in the generation of triacylglycerols. 
This effect was independent of ERK1/2 activation. It was previously shown that lack 
of lipin-1 leads to accumulation of its substrate phosphatidic acid (PA) in adipose 
tissue. We could show here that administration of PA to 3T3-L1 adipocytes increased 
phosphorylation of ERK1/2 and induced lipolysis. 
In summary, we show that Fas activation inhibits adipocyte differentiation. In mature 
adipocytes, FasL treatment induces an inflammatory response and induces ERK1/2-
dependent lipolysis. The latter is probably regulated by calcium-dependent pathways. 
Another possible mechanism involves Fas-mediated inhibition of triacylglycerol 
synthesis and subsequent activation of tryacylglycerol breakdown. These data 
underscore the role of the Fas receptor in the development of adipose tissue 
dysfunction and whole body insulin resistance. 
Zusammenfassung 
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Fas (FasR, CD95, Apo-1) gehört zur Familie der Tumor Nekrosis-Faktor Rezeptoren 
und spielt eine tragende Rolle in der Auslösung der Apoptose. Des Weiteren kann 
die Aktivierung von Fas, je nach Zelltyp, eine Entzündungsreaktion oder eine 
Zellproliferation auslösen. Wir konnten vor kurzem zeigen, dass Fas-defiziente und 
fettzellspezifische Fas-Knockout-Mäuse unter einer Fett-angereicherten Diät weniger 
schnell insulinresistent werden. Der Mechanismus dieses protektiven Effekts ist aber 
weitgehend unklar. Ziel dieser Arbeit war es, die molekularen Hintergründe dieses 
protektiven Effekts genauer aufzuklären und dabei besonders den Einfluss des Fas- 
Rezeptors auf den Metabolismus der Adipozyten zu untersuchen. 
Inkubation von differenzierenden 3T3-L1 Präadipozyten mit 2 ng/ml Fas Ligand 
(FasL) reduzierte die frühe Induktion der p44/42 MAP Kinasen (ERK1/2), welche 
wichtig für die Auslösung der Differenzierung ist. Des Weiteren reduzierte die 
Aktivierung des Fas-Rezeptors die fettzellspezifischen Markerproteine C/EBPα, 
C/EBPβ und PPARγ. 
Auch in reifen 3T3-L1 Fettzellen wurden C/EBPα  und PPARγ durch die Behandlung 
mit FasL reduziert. Zudem beeinflusste die Aktivierung des Fas-Rezeptors die 
Lipolyse zeitabhängig, mit einer Reduktion nach 2 Stunden und einer ca. 2-fachen 
Stimulation nach 12 Stunden. Die Aktivierung von Fas führte zur Phosphorylierung 
von ERK1/2 mit einem Höchstwert nach 6 Stunden. Die durch Fas ausgelöste 
Lipolyse konnte durch Inaktivierung von ERK1/2 komplett gehemmt werden. Auch 
das  Thiazolidinedion Rosiglitazone hemmte sowohl die durch Fas ausgelöste 
ERK1/2 Aktivierung wie auch die Lipolyse. 
Unser Ziel war es dann sowohl Auslöser wie auch Effekte der durch Fas ausgelösten 
ERK1/2 Aktivierung zu charakterisieren, um die Signalwege aufzuzeigen, die zu 
einer gesteigerten Lipolyse führen. 
Die Aktivierung von Fas reduzierte das PPARγ-abhängige Protein Perilipin. Früher 
konnte gezeigt werden, dass eine ERK1/2-abhängige Reduktion von Perilipin die 
Lipolyse steigern konnte. Jedoch war die Fas-induzierte Reduktion dieses 
Fetttropfen-umhüllenden Proteins ERK1/2 unabhängig. 
Des Weiteren führte eine Fas Aktivierung in Fettzellen zu einer gesteigerten 
Ausschüttung der Zytokine IL-6 und KC (Maus IL-8 Homolog) aber nicht von TNFα. 
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Hingegen konnten weder KC noch IL-6 für die ERK1/2-abhängige Steigerung der 
Lipolyse verantwortlich gemacht werden. 
Die Fas-induzierte ERK1/2-Aktivierung und Lipolyse konnten teilweise durch das 
Verwenden von extra- und intrazellulären Kalziumchelatoren sowie einem Inhibitor 
der Kalzium/Kalmodulin-abhängigen Protein Kinase II (KaMK II) gehemmt werden. 
Wir konnten jedoch keine erhöhte Aktivierung dieses Enzyms nach der Behandlung 
mit FasL messen. 
Interessanterweise reduzierte eine FasL-Behandlung die mRNA Expression und die 
Protein-Konzentration des C/EBPα-abhängigen Protein Lipin-1. Letzteres ist eine 
Phosphatase, welche in der Synthese von Triacylglycerinen involviert ist. Dieser 
Effekt war ERK1/2-unabhängig. Es ist bekannt, dass ein Fehlen von Lipin-1 zu einer 
Akkumulation seines Substrates Phosphatidsäure (PA) im Fettgewebe führt. Wir 
fanden, dass eine Behandlung von 3T3-L1-Adipozyten mit PA sowohl die 
Phosphorylierung von ERK1/2 wie auch die Lipolyse induziert. 
Zusammenfassend zeigt die vorliegende Arbeit, dass die Aktivierung des Fas- 
Rezeptors die Differenzierung von Präadipozyten hemmt. Im reifen Adipocyten löst 
eine FasL-Behandlung eine Entzündungsreaktion aus und induziert die Lipolyse 
ERK1/2-abhängig. Letztere ist möglicherweise durch kalziumabhängige Signalwege 
reguliert. Ein anderer möglicher Mechanismus beinhaltet eine durch die Fas-
Aktivierung gehemmte Triacylgycerinsynthese und eine dadurch induzierte 
Aufspaltung von Triacylglycerinen. Vorliegende Daten bestätigen eine mögliche Rolle 
des Fas-Rezeptors in der Differenzierung des Fettgewebes und der Entstehung der 
Insulinresistenz. 
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Figure 
 
  1 The Fas receptor is expressed in 3T3-L1 cells. 
  2 Fas activation reduces proliferation of preadipocytes. 
  3 Fas reduces markers of differentiation in differentiating 3T3-L1 preadipocytes. 
  4 FasL treatment induces lipolysis in 3T3-L1 adipocytes. 
  5 FasL activates ERK1/2. 
  6 Fas-induced lipolysis is dependent on ERK1/2 activation. 
  7 FasL treatment down-regulates adipogenic markers in mature adipocytes. 
  8 Rosiglitazone pretreatment reduces Fas-induced ERK1/2 phosphorylation. 
  9 Rosiglitazone reduces Fas-induced lipolysis. 
10 Activation of Fas down-regulates perilipin and HSL. 
11 Fas activation down-regulates lipin-1. 
12 Phosphatidic acid induces ERK1/2-dependent lipolysis. 
13 Fas activation does not lead to phosphatidic acid accumulation. 
14 EDTA reduces Fas-induced pERK1/2 and lipolysis. 
15 BAPTA/AM reduces Fas-induced pERK1/2 and lipolysis. 
16 The CaMKII inhibitor KN62 reduces Fas-induced pERK1/2 and lipolysis. 
17 Fas treatment does not induce CaMKII activation. 
18 FasL induces KC and IL-6 secretion, IL-6 mRNA expression and pSTAT3.  
19 Sant7 does not affect Fas-induced pSTAT3 but down-regulates pERK1/2. 
20 Treatment with JAK inhibitors or an IL-6 antibody does not reduce Fas-induced 
phosphorylation of ERK1/2. 
21 Recombinant KC does not increase lipolysis in 3T3-L1 adipocytes. 
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ATP adenosine triphosphate 
ADP adenosine diphosphate 
BMI body mass index 
CaMKII calcium/calmodulin dependent protein kinase II  
ER endoplasmatic reticulum 
ERK extracellular signal-regulated kinase 
FFAs free fatty acids 
GLUT glucose transporter 
HSL hormone-sensitive lipase 
IL-6 interleukin-6 
IR insulin receptor 
IRS insulin receptor substrate 
JAK Janus protein tyrosine kinase 
MAPK mitogen-activated protein kinase 
PA phosphatidic acid, phosphatidate 
PDE phosphodiesterase 
PPARγ peroxisome proliferator activated receptor gamma 
SOCS silencer of cytokine signalling 
TNFα tumour necrosis factor alpha 
WAT white adipose tissue 
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Glucose Metabolism 
 
Glucose as an Energy Source 
Glucose is a monosaccharide with the chemical formula C6H12O6 and belongs to the 
family of carbohydrates with the chemical makeup (CH2O)n. Containing 4.1 kcal/g, 
glucose is a very important energy source for the human body. Enzymatic breakdown 
of the disaccharide maltose, sucrose or of higher molecular carbohydrates, such as 
starches, liberate glucose in the human digestive tract. The epithelial cells of the 
small intestine absorb glucose at their apical membrane with the sodium-dependent 
glucose transporter (SGLT1). Glucose exits the cells at the basolateral membrane 
through the glucose transporter 2 (GLUT2) into the blood. Insulin stimulates the 
uptake of glucose into adipose tissue and muscle by enabling the translocation of 
glucose transporter 4 (GLUT4) to the plasma membrane. Liver takes up glucose 
through the insulin independent GLUT2 (1). Glucose is stored as glycogen in liver 
and muscle. Glycogen is made up of glucose molecules linked together by α-1,4 
linkages in the straight portions of the polymer, and by α-1,6 linkages at the frequent 
branch points. The human body can store up to approximately 1% of its weight as 
glycogen. If glycogen stores are full, the energy of glucose can be preserved by 
converting glucose to glycerol and fatty acids which are then stored as 
triacylglycerols in adipose tissue (1). 
To make the chemical energy of glucose available for the cell, glucose is degraded in 
the cytosol to pyruvate by a process known as glycolysis. This process generates 
energy even in the absence of oxygen and yields 2 molecules of adenosine 
triphosphate (ATP) per molecule of glucose (anaerobic catabolism). In the absence 
of O2, pyruvate is further metabolised to lactate. Aerobic catabolism on the other 
hand yields 30 to 32 molecule of ATP per molecule of glucose. In this case pyruvate 
is converted to acetyl CoA. Acetyl CoA enters the citric-acid-cycle in which the 
liberated energy is conserved as guanosine triphosphate (GTP) and the reduced 
electron carriers nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2). In the mitochondrial process of oxidative phosphorylation 
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these reduced nucleotides are used to generate a proton gradient that spurs the 
synthesis of ATP from adenosine diphosphate (ADP) (1). 
 
The Endocrine Pancreas 
The pancreas is a secretory organ with a weight of approximately 100 grams, which 
is located in the upper abdomen behind the stomach. The pancreas consists of two 
different parts: the exocrine pancreas, which secretes digestives enzymes and HCO3- 
into the digestive tract, and the endocrine pancreas. The major function of the 
endocrine pancreas is to keep the glucose concentration in the blood plasma at a 
constant level of around 5 mM (90 mg/dl). Such regulation is essential to provide fuel 
supply for the central nervous system which responses the most sensitive to a drop 
in glucose levels. Concentrations below 3 mM (hypoglycaemia) cause confusion, 
seizures or even coma. On the other hand, severe hyperglycemia (above 30 mM), as 
seen in the diabetic state, produces osmotic diuresis and can lead to severe 
dehydration, hypertension and vascular collapse. Furthermore, high glucose levels 
are detrimental to several tissues (glucotoxicity) (1,2).   
The endocrine pancreas consists of four different secretory cell types: α-, β-, δ- and 
F-cells. These cells are organised in structures called “islets of Langerhans” that are 
dispersed within the pancreatic tissue. The islets form approximately 2 – 3 % of the 
whole pancreas and have a diameter ranging from 75 – 300 μm. Each islet consists 
of around 3000 secretory cells. α-cells secrete glucagon. β-cells secrete insulin, 
proinsulin, C peptide and a newly described protein called amylin. The product of δ-
cells is somatostatin, and F-cells release pancreatic polypeptide. Around 70% of the 
cells in a human islet are β-cells and around 20% are α-cells. Blood supply of the 
islet is of portal origin and flows from the centre to the periphery. In humans, but even 
more pronounced in rats, β-cells are more abundant in the centre, whereas α- and δ-
cells are more frequent in the periphery (1,2). 
 
Insulin and Glucagon 
The pancreatic β-cells are the only cells in the human body that make the peptide 
hormone insulin. Transcription of the insulin gene produces preproinsulin which is 
translated into the endoplasmatic reticulum (ER). During synthesis the leader 
sequence of the preprohormone is cleaved to yield proinsulin. Proinsulin consists of 
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the domains A, B and C. In the trans-Golgi where the protein is packed into secretory 
granules, proteases cleave proinsulin at two spots and excise the C domain (C-
peptide). The resulting insulin consists of the domains A and B linked by disulfide 
bonds. Insulin is secreted together with C-peptide (1). The major trigger of insulin 
release from the β-cells is a rise in plasma glucose. Other monosaccharides 
(galactose, mannose) as well as certain amino acids and free fatty acids (FFAs) also 
stimulate insulin release. The gut hormones cholecystokinin (CCK), gastric inhibitory 
protein (GIP) and glucagon-like peptide 1 (GLP-1) are called incretins because they 
further increase the insulin response after a meal. Moreover, insulin secretion is 
under the control of the autonomous nervous system. Activation of β2-adrenergic 
receptors increases insulin release whereas α2-receptor activation inhibits it. 
Monosaccharides, amino and fatty acids have to be metabolised in the β-cell to have 
their ATP dependent stimulatory effect. Glucose enters the β-cell through GLUT2. 
The metabolism of glucose increases the amount of ATP in the cell. The increased 
concentration of ATP or the change in the ATP/ADP ratio inhibits a potassium 
channel and leads to depolarisation of the cell membrane. Depolarisation activates a 
voltage-gated calcium channel. This promotes calcium influx from the extracellular 
space which further promotes calcium release from intracellular stores. The elevated 
calcium concentration in the cell then leads to the exocytosis of insulin from secretory 
granules. Other modulators of insulin secretion act via the adenyl cyclase-cAMP-
protein kinase A and the phospholipase C-phosphoinositide pathway (1,2). 
The α-cells of the endocrine pancreas secrete glucagon, another very important 
hormone in fuel metabolism. Like insulin, glucagon is a polypeptide, but unlike insulin 
it consists of only one peptide chain. Glucagon with a length of 29 amino acids is 
processed from proglucagon in the α-cell. The intestinal L cells on the other hand 
also produce proglucagon but cleave it to yield the incretin GLP-1. Glucagon 
secretion from the α-cell is stimulated by amino acids released from protein 
digestion. The main target of glucagon is the liver and in many metabolic processes 
glucagon antagonises the effects of insulin. Glucagon is important in stimulating 
glycogenolysis, gluconeogensis, and ketogenesis (1,2). 
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Insulin Signalling 
Insulin is a powerful anabolic hormone. Binding of insulin to the insulin receptor (IR) 
leads to a cascade of signalling events that lead to glucose uptake, glycogen 
synthesis, protein synthesis, gene expression and inhibition of apoptosis - depending 
on the cellular context (3). 
The IR is a tetrameric membrane glycoprotein with intrinsic tyrosine kinase activity 
composed of two α and two β subunits. Insulin binds to the α subunit which contains 
a ligand binding domain and a cysteine-rich region. The β-subunit is a single-pass 
transmembrane protein with a cytoplasmic catalytic domain and an ATP-binding site. 
Disulfide-bounds connect the α and β subunits as well as the two α subunits. Insulin 
binding probably brings the two α subunits closer together and causes allosteric 
interactions between the two α and β pairs. The resulting conformational change 
allows ATP to bind to the β subunit which enables the autophosphorylation of the IR 
and, subsequently, the phosphorylation of intracellular protein substrates (1,3). 
The IR substrate (IRS) proteins play an essential role in insulin signal transduction. 
They are phosphorylated by the IR on specific tyrosine residues. Once 
phosphorylated the IRSs serve as docking sites for additional signalling molecules. 
The IRS family is composed of 4 closely related members (IRS-1 to -4) and the more 
distantly related homolog, Gab-1. Knockout of IRS-1 cause severe growth retardation 
and mild insulin resistance. Ablation of IRS-2 induces peripheral insulin resistance 
and impaired growth of pancreatic β-cells. IRS-1 and IRS-2 have widely overlapping 
tissue distribution which points to specific roles of each protein. Ablation of IRS-3 
does not cause a clear phenotype, whereas lack of IRS-4 is associated with modest 
growth retardation and insulin resistance. Gab-1 seems to be involved in hepatic 
growth rather than in insulin signalling (3-7). 
Proteins that contain a Src homology domain 2 (SH2) get activated by docking to 
certain phosphorylated tyrosine residues on IRS. One of these proteins is 
phosphatidylinositol 3-kinase (PI 3-kinase). Activated PI 3-kinase generates 
phosphatidyl inositol-3,4,5-triphosphate (PIP3) from phosphatidyl inositol-4,5-
biphosphate (PIP2). PIP3 acts as an intracellular messenger, leading to the activation 
PI-dependent kinase (PDK). PDK is a Ser/Thr kinase which activates Akt (protein 
kinase B, PKB). Akt then phosphorylates its substrate of 160 kDa (AS160), which is a 
Rab-GTPase activating enzyme. This insulin dependent signalling pathway finally 
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leads to the insertion of GLUT4 into the plasma membrane and increased glucose 
uptake by the cell (1,8). 
Akt activation can also lead to phosphorylation of glycogen synthase kinase-3 (GSK-
3). Phosphorylation inactivates GSK-3 which in turn is no longer able to inactivate 
glycogen synthase through phosphorylation. Thus, activation of this insulin signalling 
pathway leads to the synthesis of glycogen in liver and muscle. In the adipocyte, Akt 
activates the cyclic nucleotide phosphodiesterase 3B (PDE 3B), thereby reducing 
cAMP levels in the cell and, consequently, decreasing lipolysis. Furthermore, Akt has 
the ability to phosphorylate proteins that regulate lipid synthesis, protein synthesis 
and cell survival (1,3,9). 
Insulin achieves its effects not only via PI 3-kinase dependent pathways. Direct 
phosphorylation of SHC (Src homology, C terminus) by the IR and activation of 
growth factor receptor binding protein 2 (GRB2) through IRS leads to activation of the 
mitogen-activated protein kinase (MAPK) pathway (1). 
 
Insulin Action in Different Organs 
In general, insulin promotes anabolism and reduces catabolic processes. In the liver, 
insulin increases the formation of glycogen from glucose by inducing the transcription 
of glucokinase and through activation of glycogen synthase. The liver takes up 
glucose via GLUT2, which is not insulin responsive. However, by inducing glycogen 
synthesis insulin increases liver glucose uptake indirectly. Glycogen breakdown is 
inhibited by insulin through inhibition of glycogen phosphatase and glucose-6-
phosphatase. Moderate increases in insulin levels allow gluconeogenesis to persist 
while the hepatocyte stores the newly formed glucose 6-phosphate as glycogen 
rather than releasing glucose to the blood. At high concentration however, insulin 
also inhibits the gluconeogenic pathway. Insulin stimulates pyruvate generation from 
glucose and pyruvate oxidation with the consequence that this substrate is no longer 
available for gluconeogenesis. Moreover, insulin diminishes transcription of the 
phosphoenolpyruvate carboxykinase gene which encodes for a key enzyme in 
gluconeogenesis. Insulin further promotes the formation of triacylglycerols in 
hepatocytes and their export in very-low-density lipoproteins (VLDL). Finally, insulin 
inhibits proteolysis and increases protein synthesis in the liver (1). 
Striated muscle is the main tissue of insulin mediated glucose disposal. As described 
earlier, insulin promotes the insertion of GLUT4 into the plasma membrane of muscle 
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and adipose tissue. By this process insulin increases glucose uptake of muscle, and 
it favours the subsequent conversion of glucose to glycogen through activation of 
hexokinase and glycogen synthase. Furthermore, insulin increases glucose 
breakdown and oxidation. Like in the liver insulin also has an anabolic effect on 
protein metabolism in muscle (1). 
In adipose tissue, similar to muscle, insulin stimulates glucose uptake via GLUT4. 
Insulin promotes glycolysis to generate glycerol-3-phosphate and stimulates pyruvate 
dehydrogenase and acetyl CoA carboxylase to synthesise fatty acids. Insulin 
enhances the esterification of these molecules to form triacylglycerols. As mentioned 
earlier, insulin also inhibits the breakdown of triacylglycerols (lipolysis) by decreasing 
the activity of hormone-sensitive lipase (HSL). Finally, insulin induces the synthesis 
of lipoprotein lipase (LPL). LPL is exported from the adipocytes to the surface of the 
endothelial cells. There LPL acts on triacylglycerols in chylomicrons and thereby 
liberates fatty acids for triacylglycerol built up in fat cells (1). 
 
  
Introduction – White Adipose Tissue 
White Adipose Tissue 
 
Function and Composition of White Adipose Tissue 
The primary function of white adipose tissue (WAT) is to store energy in the form of 
triacylglycerols during times of energy excess. In times of energy requirement, stored 
lipids are released as FFAs and glycerol. As large energy reserve of the body and 
insulin responsive organ, adipose tissue has a major impact on energy flux and 
plasma lipid levels. Adipose tissue is now also appreciated to be an endocrine organ 
that secretes multiple factors controlling whole body metabolism (10). 
WAT not only consists of adipocytes but also harbours other cell types. This so called 
stromal vascular fraction includes cells types such as preadipocytes, endothelial 
cells, pericytes, monocytes, macrophages, and others. All of these cells have an 
important function in maintaining adipose tissue homeostasis. For example, 
endothelial cells and pericytes make up the vasculature of adipose tissue and 
thereby enable adipose tissue growth and development. Macrophages are thought to 
be necessary for the clearance of necrotic adipocytes, which particularly seems to 
play a role in obesity and its associated complications (11). 
  
Adipocyte Commitment and Differentiation 
The adipose lineage arises from multipotent stem cells of mesodermal origin within 
the vascular stroma of WAT. In an initial commitment step, known as determination, 
the precursor cells become preadipocytes which are restricted to the adipocyte 
lineage but show no special morphological features (10,12). 
Adipocyte differentiation consists of a coordinated cascade of transcriptional events, 
which turns preadipocytes into mature, lipid filled adipocytes. The most important 
members of the adipogenic program are the transcriptional factors of the CCAAT-
enhancer-binding protein (C/EBP) family and the peroxisome proliferator activated 
receptor γ (PPARγ). The first transcriptional factors to be expressed are C/EBPβ and 
C/EBPδ. The transcriptional activation of C/EBPβ is controlled by the cAMP-response 
element binding protein (CREB). However, at first, C/EBPβ lacks DNA-binding 
capacity because it forms heterodimers with the dominant negative isoform CHOP-10 
(C/EBPζ). CHOP-10 is subsequently down-regulated and C/EBPβ is freed. 
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Subsequent hyperphosphorylation enables C/EBPβ to bind DNA. Together with 
C/EBPδ it induces C/EBPα and PPARγ. PPARγ and C/EBPα positively regulate each 
other’s expression. PPARγ is the central regulator of adipogenesis and responsible 
for the activation of genes involved in fatty acid binding, uptake and storage. C/EBPα 
was shown to be required for the acquisition of insulin sensitivity (10,12). 
For the differentiation of 3T3-L1 preadipocytes, a process called mitotic clonal 
expansion (MCE) was shown to be crucial. MCE consist of about two rounds of 
mitosis after the postconfluent growth-arrested cells are induced to differentiate. The 
p42 and p44 MAPKs, also called extracellular signal-regulated kinase (ERK) 1 and 2, 
play an essential role in this process (13).  
 
Adipose Tissue Distribution 
In humans WAT begins to develop early in the second trimester and at the time of 
birth it is well developed. Human WAT is dispersed throughout the body with 
subcutaneous and intra-abdominal depots representing the main compartments for 
triacylglycerol storage. Subcutaneous WAT is localised directly under the skin with 
major depots in the buttocks, thighs, and abdomen. Intra-abdominal WAT represents 
the fat inside the peritoneal cavity and can be further divided into an omental, a 
retroperitoneal and a visceral compartment. The latter consists of a mesenteric and a 
perirenal depot. Women have a higher percentage of body fat than man. However, 
pre-menopausal women store only 6% of body fat as visceral adipose tissue whereas 
in men it accounts for around 20% of total body fat. Fat distribution changes with age. 
Subcutaneous fat decreases and intra-abdominal fat increases making sex-related 
differences less prominent (11,14,15).  
In the context of obesity fat distribution can be estimated by measuring the ratio of 
waist to hip circumference (WHR). People with low WHR accumulated more 
subcutaneous adipose tissue and exhibit so called pear-shaped obesity. High WHR 
is an index for accumulation of more visceral adipose tissue named apple-shaped or 
visceral obesity. This classification gained considerable interest as people with 
visceral obesity are at high risk to develop the metabolic syndrome and diabetes 
whereas people with subcutaneous obesity are not. There are two possible not 
mutually exclusive explanations for this phenomenon. The first is based on the fact 
that visceral fat drains its products (FFAs, cytokines and adipokines) into the portal 
circulation where they act primary on the liver to affect metabolism. The second is 
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based on the concept that adipocytes from different depots have different properties 
making them more or less prone to cause metabolic complications in the obese state. 
Indeed, visceral and subcutaneous adipose tissues have a different gene expression 
profile and show several other differences. For example, visceral adipose tissue 
secretes more interleukin-6 (IL-6), a cytokine involved in the development of insulin 
resistance and diabetes. Diabetes can be treated with thiazolidinediones (TZDs), 
which are PPARγ agonists. Interestingly, amelioration of the metabolic profile during 
treatment is associated with a selective increase of subcutaneous adipose tissue 
whereas visceral fat is unchanged. Furthermore, visceral WAT is more responsive to 
β-adrenoreceptor-mediated lipolysis. Exercise, which is known to improve 
metabolism in diabetics, consequently leads to more visceral than subcutaneous fat 
loss. Thus, the human body not only stores triacylglycerols in different locations, but 
the amount of these individual depots and the balance between them play an 
important role in complications associated with obesity (14,15).  
 
Adipose Tissue Expansion 
From a thermodynamic point of view, an increase in adipose tissue results from a 
decrease of energy expenditure or an increase in energy intake with food. The 
surplus of energy is stored as glycogen in liver and muscle and as triacylglycerols in 
WAT. As glycogen deposition to liver and muscle is limited, the main energy storage 
organ in mammals is adipose tissue. The adipocyte is unique among cells in that 
more than 95% of the cell volume consists of stored triacylglycerols and its diameter 
can change from 25 to 200 μM. WAT is the only tissue in the body that can markedly 
change its mass in adulthood. Thus, fat mass can range from 2 to 3% of body weight 
in extremely well trained athletes to 60 – 70% in massively obese humans. Gain of 
fat mass consists of two possible processes: first, enlargement of adipocytes 
(hypertrophy) and second: commitment as well as proliferation of preadipocytes and 
their subsequent differentiation into new adipocytes (hyperplasia) (11,16-19). 
However, it was shown that total adipocyte number as well as the different amount of 
adipocytes between lean and obese humans is established during childhood and 
adolescence. During adulthood it was postulated that the total number of adipocytes 
does no longer change, even during weight gain. Of note, the authors of that study 
looked at subjects with early onset obesity and they could not role out that there is 
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recruitment of additional adipocytes from precursor cells with increasing weight gain 
in adult subjects (20). 
 
Triacylglycerol Synthesis 
Triacylglycerols are synthesized through step-wise addition of acyl groups to glycerol-
3-phosphate. Since in adipocytes glycerol kinase activity is negligible, glycerol-3-
phosphate is derived from glucose or produced by glyceroneogenesis from 
gluconeogenic substrates depending on nutritional status. The acyl moieties derive 
either from de novo fatty acid synthesis with glucose as the main source (lipogenesis) 
or from FFAs taken up from the plasma (21). 
The first acyl group is transferred to glycerol-3-phosphate by glycerol-3-phosphat 
acyltranferase (GPAT) yielding lisophosphatidate (LPA). LPA is then converted to 
phosphatidate (PA) through addition of another acyl group by acylglycerol-3-
phophate acyltransferase (AGPAT). PA phosphatidase-1 (PAP1), better known as 
lipin-1, dephosphorylates PA producing diacylglycerol (DAG). Diacylglycerol 
acyltransferase (DGAT) adds the last acyl group to diacylglycerol to form 
triacylglycerol. The acyl transferases constitutively reside in the ER whereas lipin-1 is 
cytosolic and only transiently associates with the ER membrane to perform the PAP1 
reaction (22). 
Among the mentioned enzymes lipin-1 is special as it can also act as a transcriptional 
coactivator. In this function nuclear lipin-1 amplifies the expression of genes involved 
in fatty acid oxidation. Moreover, lipin-1 plays an important role during adipocyte 
differentiation and in the maintenance of adipocyte-specific gene expression by 
interacting with PPARy (22,23). 
Mutations in the lipin-1 gene cause lipodystrophy and insulin resistance in mice (24). 
Furthermore, these fatty liver dystrophy (fld) mice show an increase of the lipin-1 
substrate PA in WAT (25) which might play an important role as second messenger 
in this tissue. Mice that over-express lipin-1 in their mature adipocytes show 
increased adiposity and accelerated diet-induced obesity. However, these animals 
have increased insulin sensitivity (26). The importance of lipin-1 is further underlined 
by the fact that in mice and healthy male humans, lipin-1 expression correlates with a 
better metabolic profile (27). 
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Triacylglycerol Storage   
Adipocytes store triacylglycerols in the form of one or more lipid droplets. These 
organelles presumably emerge from the ER lipid bilayer or a subset of ER 
membranes. Their core of triacylglycerols is surrounded with a phospholipid 
monolayer and coating proteins of the perilipin family. Besides stabilisation these 
proteins likely execute coordinative functions in the metabolism of the lipid droplet 
(28). The family founding member perilipin for example is an effective shielding 
protein that reduces the access of cytosolic lipases to the triacylglycerols. But apart 
from that barrier function, perilipin  also seems to be needed for hormonally 
stimulated lipolysis since β-adrenergic receptor agonists fail to maximally stimulate 
this process in  perilipin null adipocytes (29).        
 
Lipolysis 
Lipolysis describes the step-wise hydrolysation of triacylglycerols to diacylglycerols, 
monoacylglycerols and glycerol and FFAs by lipases (esterases). One triacylglycerol 
molecule is usually completely broken down to one molecule of glycerol and three 
molecules of FFAs. Nevertheless glycerol and FFAs are not released from the cell in 
the ratio 1:3 since some FFAs are re-esterified. But, because of the low glycerol 
kinase activity in adipocytes, only insignificant amounts of glycerol are re-utilized 
(30). 
Three enzymes that catalyse triacylglycerol breakdown are known so far. HSL 
hydrolyses triacylglycerols to diacylglycerols and diacylglycerols to 
monoacylglycerols. Monoglycerid lipase (MGL) breaks down monoacylglycerols to 
glycerol and FFAs. The function of the adipocyte-specific triglyceride lipase (ATGL) 
seems to be the catalysis of the first step of triacylglycerol catabolism. Importantly, 
only HSL is responsive to hormone stimulation (30). 
HSL exists in three isoforms ranging from 84 to 130 kDa. The enzyme contains three 
domains, a catalytic domain, a regulatory domain with several phosphorylation sites, 
and a variable N-terminal domain that can interact with other proteins or with lipids. 
The activity of the enzyme is dependent on serine phosphorylation. Increased activity 
of HSL is induced through phosphorylation on the Ser-563 residue by protein kinase 
A (PKA). In contrast, Ser-565 is phosphorylated in the basal state and prevents 
phosphorylation on Ser-563, thus decreasing lipase activity. Ser-659 and Ser-660 
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were also found to be activity controlling sites. Furthermore, the MAPKs ERK1/2 can 
activate the enzyme through phosphorylation on Ser-600 (31). 
Lipolysis is typically stimulated by beta1,2,3-adrenergic receptor agonists. In the 
physiological context the catecholamine hormones noradrenaline and adrenaline are 
the most important of this class of substances. In cell culture the β1,2-receptor agonist 
isoproterenol is often used as a positive control when looking at lipolysis. 
Adrenoreceptors are coupled to Gs-proteins that activate adenylate cyclase, so that 
the production of cyclic AMP (cAMP) increases upon receptor stimulation. Increased 
levels of cAMP activate PKA which phosphorylates HSL leading to breakdown of 
triacylglycerols. Insulin on the other hand is a powerful inhibitor of lipolysis. IR 
stimulation leads to increased activity of phosphodiesterase 3 which converts cAMP 
to 5’-AMP thereby decreasing PKA and, subsequently, HSL activity. Additionally, 
humans have α2A-adrenoreceptors that decrease lipolysis through their interaction 
with Gi-proteins and subsequent inhibition of adenylate cyclase (30,31). 
Besides the well established stimulation by beta adrenergic receptor agonists, 
lipolysis can also be increased by other compounds. The cytokine tumour necrosis 
factor alpha (TNFα) stimulates lipolysis through activation of ERK1/2 and down-
regulation of the lipid droplet coating protein perilipin (32). Furthermore, the cytokine 
IL-6, which is secreted by working muscle, has lipolytic activity in humans (33). In 
experiments performed with stromal vascular fractions containing newly differentiated 
adipocytes from human donors IL-6 as well was shown to signal via the ERK1/2 
pathway (34). Studies in primary cells and cell lines suggest that lipolysis can also be 
positively influenced by a rise in intracellular calcium (Ca) levels that induce different 
signalling pathways involving calcium/calmodulin dependent protein kinase II 
(CaMKII), protein kinase C (PKC) and ERK1/2 (31). On the other hand, increased Ca 
seems to inhibit lipolysis in human adipocytes through induction of PDE activation 
and a subsequent decrease in cAMP (35). 
   
Adipose Tissue as an Endocrine Organ 
Since the 1980s it became clear that adipose tissue not only acts as energy storing 
compartment but also as an endocrine organ. Several factors are highly expressed in 
the adipocyte and get secreted by the cell. These adipose tissue derived molecules 
are generally termed adipokines. Adiponectin is the adipokine with the most restricted 
expression pattern. There are very few reports of adiponectin being produced by 
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other cells than adipocytes. Other adipokines such as leptin, however, show 
expression patterns that are less fat cell-specific. Moreover, hormones like resistin, 
omentin, and visfatin are made by several other tissues, as well (11). 
Leptin is a 16 kDa protein encoded by the ob gene. The levels of leptin in circulation 
correlate directly with adipose tissue mass. Control of appetite is the primary role of 
leptin. Mice as well as human subjects with a mutation in the leptin (obese, ob/ob) or 
the leptin receptor (diabetes, db/db) gene are massively obese. Binding of leptin to its 
receptor on neurons in the hypothalamus provides the brain with information 
regarding energy stores of the body. By modulation of several orexigenic (appetite 
stimulating) and anorexigenic (appetite suppressing) peptides leptin decreases food 
intake and promotes weight loss. Besides adipose tissue, leptin is released by the 
stomach. Thereby it also influences short-term regulation of appetite and meal size 
together with other satiety peptides. On the other hand, fasting was shown to 
significantly reduce leptin levels and this change was much greater than the loss in 
adipose tissue. Several other studies have further supported the importance of leptin 
in the neuroendocrine response to starvation. Leptin is involved in other biological 
processes as well, including reproduction (initiation of human puberty), 
haematopoiesis, angiogenesis, bone formation and wound healing. Furthermore, 
leptin exerts a proinflammatory role, while at the same time protecting against 
infections (36,37).  
Adiponectin (ACRP30, adipoQ, apM1, or GBP28) is a 30 kDa protein induced 
during adipocyte differentiation. The adipokine consists of an N-terminal collagenase 
and a C-terminal globular domain. After being synthesised adiponectin forms trimers, 
which then aggregate to polymers. In circulation, adiponectin exists as either a trimer, 
a hexamer (called the low molecular weight (LMW) form), or as multimeric forms of 
12 to 18 subunits (high molecular weight (HMW) form). There are three possible 
receptors for adiponectin. One is mainly in the liver (AdipoR2), one in skeletal muscle 
(AdipoR1), and one on endothelial cells and smooth muscle cells (T-cadherin). 
Adiponectin reduces glucose output of the liver and suppresses gluconeogenic 
genes. It was also shown to have potent cardioprotective effects, and 
hypoadiponectinemia is highly correlated with cardiovascular disease (11,38). 
Adiponectin does not increase with increased body fat mass like leptin. On the 
contrary, adiponectin serum levels are inversely correlated with obesity. Furthermore, 
the adipokine is significantly decreased in patients with type II diabetes. However, 
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several insulin resistant populations exhibit this relationship independent of obesity. 
The mechanism linking decreased adiponectin levels to the insulin resistant state is 
not completely clear. Administration of adiponectin to mice results in decreased 
glucose, FFAs and triacylglycerol levels. Adiponectin partly seems to mediate its 
positive effects on metabolism through activation of the 5`-AMP-activated protein 
kinase (AMPK) in muscle and liver. This leads to increased fatty acid oxidation and 
glucose uptake in myocytes in vitro. In mice, this adiponectin effect inhibits 
expression of proteins involved in gluconeogenesis in liver and thereby decreases 
glucose levels. Increased oxidation of FFAs in muscle triggered by adiponectin might 
have a positive effect on insulin signalling in muscle and on whole body insulin 
sensitivity. The low-inflammatory state associated with obesity might have a negative 
impact on adiponectin, since the cytokines TNFα and IL-6, which are both increased 
in obese subjects, inhibit adiponectin gene expression. On the other hand, 
adiponectin has anti-inflammatory properties and reduces the production of IL-6 and 
TNFα, while inducing the anti-inflammatory cytokines IL-10 and IL-1 receptor 
antagonist (11,36,38,39). 
Resistin is a 12 kDa protein that is predominantly expressed by adipocytes in mice 
whereas the primary source in humans seems to be macrophages. It belongs to a 
family of resistin-like molecules, RELM (also called “found in inflammatory zone”, 
FIZZ). The protein known as FIZZ-3 was called resistin because of its ability to 
induce mainly hepatic insulin resistance in mice. Resistin levels are elevated in both 
diet-induced obesity and genetic mouse models of obesity/diabetes (ob/ob and db/db 
mice). However there is no consistent link between resistin levels and either obesity 
or insulin resistance in humans. In human subjects resistin may act as a mediator of 
the insulin resistance associated with sepsis and possibly other inflammatory 
conditions (36,38). 
Introduction – Obesity and Type 2 Diabetes 
Obesity and Type 2 Diabetes 
  
The Epidemiology of Obesity 
Obesity is generally defined as excess body fat. However, the definition of excess is 
not clear-cut. Accumulation of adipose tissue develops gradually and there is no clear 
separation into normal and abnormal. Because direct measurement of body fat 
content is difficult, the body mass index (BMI) is used as an indirect index to define 
obesity. The BMI is calculated as weight in kilograms divided by height in meters 
squared and thus, sets total body weight (not total body fat) in relation to height. 
Currently, a healthy weight in adults is defined as a BMI between 18.5 and 24.9 
kg/m2, overweight as a BMI of or greater than 25 kg/m2, obesity as a BMI of or 
greater than 30 kg/m2 and extreme obesity as a BMI of or greater than 40 kg/m2. In 
the United States of America, overweight in children is defined as a BMI at or above 
the 85th percentile and obesity as BMI at or above the 95th of the 200 CDC growth 
charts (40). 
In the USA the prevalence of adults that are overweight increased from 44.9 to 
66.2% between 1960 and 2004. Among them, mainly the prevalence of obesity and 
extreme obesity increased from 13.3 to 32.9% and from 0.9% to 5.1% respectively, 
whereas the percentage of people that are overweight but not obese remained stable 
during that period. The prevalence of obesity changed little between 1960 and 1980. 
However, between 1980 and 2000 the percentage of obesity more than doubled from 
15 to 30.9 %. Until 2004 obesity further increased to 31.7% in men and 34% in 
women. The dramatic increase of people with excess body weight is not limited to the 
adult population. In the USA the prevalence of overweight children (2 – 19 years of 
age) increased from 5.1 to 17.1% between 1974 and 2004 (40). 
The increasing prevalence of obesity is not experienced by the USA alone but is 
becoming a worldwide phenomenon. By 2010 one out of ten school children in 
Europe is expected to be obese. Also in Switzerland obesity prevalence in adults and 
children has clearly increased in the past three decades. Between 1960 and 2002 the 
prevalence of overweight in Swiss children (6 – 12 years of age) increased from 5.1% 
in boys and 5.8% in girls to 19.9% and 18.9%, respectively. During the same time 
period obesity in Swiss children increased from 0.25 to 7.4% in boys and from 0.41 to 
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5.7% in girls. The percentage of obese Swiss adults by 2004 was 14.2% for men and 
12.5% for women (40-43). 
The onset and progression of obesity have multiple determinants such as genetic 
background, environmental factors (i.e. diet), behaviour factors (i.e. inactivity) and 
socioeconomic status. Likely a gene-environment interaction in which genetically 
susceptible individuals respond to the modern western environment with unlimited 
access to palatable energy-dense foods and reduced demand for energy 
expenditure, contributes to the current high prevalence of obesity. The clinical 
problem of overweight and especially obesity lies in its strong association with a 
number of chronic diseases such as hypertension, dyslipidemia, cardiovascular 
disease, non-alcoholic fatty liver disease, certain cancers, insulin resistance and 
diabetes mellitus, and others (40). 
 
Adipose Tissue Dysfunction and Inflammation in Obesity 
As described earlier, adipose tissue stores energy in form of triacylglycerols. Through 
sequestration of lipid molecules, especially FFAs, away from tissues, which are not 
suited for lipid storage, adipose tissue protects the body from toxic effects of these 
compounds (lipotoxicity). As outlined above, WAT plays also a role as endocrine 
organ. In healthy subject, factors secreted by adipocytes regulate whole-body 
metabolism and neuroendocrine control of food intake. During prolonged intake of 
excess energy and the resulting development of obesity, WAT becomes 
dysfunctional and inflamed. This pathological condition of WAT has a negative impact 
on many organs and tissues like muscle, liver, pancreas (44).   
Hyperphagia induces increased energy deposition in WAT as triacylglycerols and 
consequently causes the adipocytes to enlarge (hypertrophy). Hypertrophied fat cells 
show a different pattern of secreted factors. For example, leptin and IL-6 are up-
regulated as well as monocyte chemoattractant protein-1 (MCP-1). MCP-1 enhances 
macrophage infiltration into WAT. Lean subjects normally exhibit a macrophage 
content of under 10% in WAT. In obese humans however, nearly 40% of the cells in 
adipose tissue are macrophages (45). In obesity macrophages form crown-like 
structures around necrotic adipocytes. This gives rise to the hypothesis that 
adipocytes can enlarge to a certain size before they undergo cell death, and 
macrophages clear the resulting debris. Macrophages also secrete MCP-1 to attract 
more inflammatory cells. Furthermore, they secrete inflammatory cytokines like 
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TNFα, IL-6 and IL-1β as well as the adipokine resistin in humans. Macrophages are 
the major source of TNFα produced by WAT and the origin of around 50% of WAT-
derived IL-6. Inflammatory cytokines negatively affect the secretion pattern of 
adipocytes. TNFα for example decreases the secretion of adiponectin. Moreover, 
inflammatory cytokines have a dramatic influence on adipocyte function resulting in 
insulin resistance, increased lipolysis and decreased lipogenesis (36,44,46). 
TNFα down-regulates PPARγ on multiple levels. PPARγ is an essential regulator of 
adipogenesis and is required for the maintenance of mature adipocyte function. On 
the other hand, TNFα stimulates lipolysis through multiple mechanisms. TNFα 
reduces insulin signalling and thereby inhibits the antilipolytic actions of insulin in 
adipocytes. TNFα increases cAMP levels in the cell by down-regulation of inhibitory 
G-protein coupled receptors. Finally, TNFα decreases perilipin expression via an 
ERK1/2 mediated pathway and also down-regulates the function of this lipid-coating 
protein (32,44). 
In obesity, as a result of permanent nutritional overflow, WAT additionally suffers 
from organelle dysfunction, impacting mitochondria an ER. The so called ER-stress 
leads to the activation of the unfolded protein response (UPR). Besides the 
attenuation of protein translation and the increased chaperone transcription, ER 
stress and the UPR are linked to major inflammatory and stress signalling networks. 
UPR induces inflammatory genes in many cell types. Furthermore, ER stress induces 
the activation of the enzyme c-Jun N-terminal kinase (JNK). JNK1 inhibits insulin 
signalling through serine phosphorylation of IRS-1. One possible action of JNK is 
also the phosphorylation and inhibition of PPARγ. However, the importance of ER-
stress in adipocyte insulin resistance and inflammation warrants further investigation 
(47). 
Besides the afore mentioned disturbances originating from increased cell volume, 
inflammation and ER dysfunction, the adipose tissue is also confronted with oxidative 
stress and probably metabolic stress. The latter is caused by the increased 
availability of glucose and fatty acids as well as by the resulting metabolites. All those 
stresses are connected to each other and lead to signalling through a network of 
stress-sensing kinases. These enzymes including JNK1/2, p38 MAPK, ERK1/2, 
IKKβ, mTOR and PKCs linking the state of overnutrition to cellular dysfunction (48). 
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From Insulin Resistance to Type 2 Diabetes 
In obesity, WAT is not longer able to store energy properly resulting in increased FFA 
release. Additionally adipose tissue is a source of inflammatory cytokines. The 
excess circulating FFAs cause accumulation of lipids in skeletal muscle, the liver and 
β-cells of the pancreas. Besides the negative impact of this ectopic fat deposition, 
increased release of inflammatory cytokines impair the metabolic function of these 
organs. The combined action of both FFAs and cytokines produces whole body 
insulin resistance (44). 
Skeletal muscle is the main insulin responsive tissue in the body. In muscle, FFAs 
activate several protein Ser/Thr kinases which phosphorylate IRS proteins on serine 
residues and thereby inhibit insulin signalling. Fatty-CoA and diacylglycerol for 
example activate protein kinase C theta (PKCθ).  PKCθ then inactivates IRS 
signalling through phosphorylation. FFAs also inhibit Tyr phosphorylation of the IR 
and IRS proteins. Toll-like receptor (TLR) 2 and 4 may also play a role in FFA-
induced insulin resistance in muscle. Ceramides are lipid metabolites which are 
increased in obesity in rodents and humans. Increased ceramide synthesis induced 
by TNFα or saturated FFAs inhibit insulin signalling on the level of AKT/protein 
kinase B (PKB) activation. Further, TNFα impairs insulin signalling by inducing 
Ser/Thr phosphorylation of IRS proteins. This effect of TNFα is mediated by JNK1 
and MAP4K4 in muscle (44). 
FFA overload of the liver causes triacylglycerol accumulation in hepatocytes termed 
hepatosteatosis, and consequently hepatic insulin resistance. The adipose tissue 
derived cytokine IL-6 may also play an important role in inducing hepatic insulin 
resistance (46). 
In the insulin resistant state more insulin is needed to achieve normal glucose levels 
(normoglycemia). The secretion of adequate amounts of insulin depends on both β-
cell mass and function. The pancreas reacts to the increased insulin demand through 
proliferation of β-cells. Multiple factors influence the balance of β-cell proliferation and 
apoptosis. For example, hyperglycemia induces production of the cytokine interleukin 
1 beta (IL-1β) by β-cells. Low concentrations of IL-1β were shown to induce 
Fas/FLIP-mediated proliferation of β-cells and this is probably part of the adaptive 
response in the insulin resistant state. On the other hand, high concentrations of IL-
1β induce apoptosis of β-cells. Saturated fatty acids are also highly toxic for β-cells. 
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TNFα in combination with other adipose tissue derived cytokines probably further 
potentate this effect. Insulin resistant individuals who fail to adopt properly finally 
develop type 2 diabetes mellitus. In the latter, glucose concentration in the blood is 
permanently elevated with detrimental effects for the body (49,50).  
Introduction – The Fas Receptor 
The Fas Receptor 
 
Fas and its Ligand FasL 
Fas was first described in 1989 as surface molecule on lymphocytes that triggers cell 
death (51). The gene that encodes the Fas receptor (FasR, CD95, Apo-1) is located 
on mouse chromosome 19 and on human chromosome 10 (52). Fas ligand (FasL, 
CD95L) is located on chromosome 1 in both mice and humans (53,54). 
Fas is a type I transmembrane protein that belongs to the tumour necrosis factor 
(TNF)/nerve growth factor (NGF) receptor superfamily (55). Members of this family 
share characteristic extracellular cysteine-rich domains, which control ligand binding 
and spontaneous self-assembly into trimers (51). Fas is activated by Fas ligand, a 
type II membrane protein and typical member of the TNF ligand family (56). The 
ability of Fas to induce apoptosis upon ligand binding depends on a conserved part 
of the cytoplasmic domain termed death domain (DD). The death domain consists of 
six α-helices, which bind to other DD-containing proteins. Due to their death domains 
a subset of TNF receptor superfamily members including TNF receptor 1 are often 
termed death receptors. However, the term death domain as well as death receptor 
are misleading as those receptors can also induce pathways leading to proliferation 
and survival instead of death (51). 
The human Fas gene consists of nine exons and several transcripts are derived from 
the gene through alternative splicing. The transcripts give rise to multiple soluble 
variants of Fas which have been shown in vitro to have a negative regulatory role on 
membrane expressed Fas. Furthermore, human thymocytes express a membrane-
bound form of Fas that has been described to act as a decoy receptor for Fas. FasL 
can exist in membrane bound and soluble form but the Fas-stimulatory capacity of 
membrane-bound FasL is magnitudes higher compared to soluble FasL (57). 
In the adult mouse Fas and FasL are expressed in several tissues including the 
thymus, lung, spleen, small intestine, large intestine, seminal vesicle, prostate, uterus 
and adipose tissue [(58), and own observation]. In mice naturally occurring mutations 
of Fas and FasL cause lymphoproliferation (lpr) and generalized lymphoproliferative 
disease (gld). These mutant animals are important for the determination of the 
biological role of Fas and FasL (59) 
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Fas Signalling 
Fas monomers spontaneously self-assemble to trimers in the cell membrane. Binding 
to FasL or agonistic Fas antibodies presumably induces a conformational change of 
these trimers allowing the recruitment of DD-containing adaptor proteins. There are 
three Fas DD-binding molecules known so far: the Fas Associated Death Domain 
protein (FADD/MORT-1), the death associated protein Daxx, and the Receptor 
Interacting Protein (RIP) (51). 
Fas-induced apoptosis is mediated with the help of the adaptor protein FADD. FADD 
binds to pro-caspase 8 and/or pro-caspase-10. The resulting complex is called death 
inducing signalling complex (DISC). At the DISC pro-caspase-8 (and/or -10) converts 
itself to active caspase 8 (also known as FADD-like interleukin-1 converting enzyme, 
FLICE). Caspases are cysteine proteases that cleave their substrates at aspartic acid 
residue. In cells of type I, DISC formation leads to the cytoplasmic caspase cascade 
in which the initially activated caspases activate other pro-caspases. In type II cells 
DISC formation is strongly reduced and the apoptotic signal is amplified through 
mitochondrial destabilisation and release of pro-apoptotic molecules including 
cytochrome c. Both pathways converge on caspase 3 activation and programmed 
cell death (51,60). 
Fas activation can also have other consequences than the induction apoptosis. 
FADD binds to FLICE Inhibitory Protein (FLIP). FLIP is a caspase 8 homologue that 
lacks catalytic activity.  Like caspase 8, FLIP is essential for embryonic survival (62). 
FLIP inhibits the induction of apoptosis by binding to FADD instead of caspase 8. 
Furthermore, FLIP seems to mediate Fas-induced proliferation through activation of 
ERK1/2. ERK1/2 on the other hand up-regulates FLIP which may create a positive 
feedback loop that favours proliferation and inhibits cell death (51). 
Daxx is a transcriptional repressor that binds to Fas independent of FADD. Daxx is 
mainly localised in the nucleus. Apoptosis signalling kinase 1 (ASK1) is needed for 
cytoplasmic localisation of Daxx as well as for the interaction with Fas. Daxx can 
enhance Fas-induced apoptosis. However, during development Daxx seems to be 
required as survival factor. Further, studies using RNAi for Daxx in cell lines showed 
increased apoptosis as well sensitisation of cells to Fas-, UV- and TNFα-induced cell 
death, suggesting an anti-apoptotic role for Daxx (51,61). 
The death domain containing RIPs (RIP, RIP2, RIP3, RIP4) possess serine/threonine 
kinase activity and associates with Fas or with FADD or FLIP. In the vivo context RIP 
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appears to be a survival factor rather than an inducer of proliferation or apoptosis. 
RIP2 can mediate Fas-induced differentiation through activation ERK. RIP may also 
play a role in Fas-induced inflammation since it activates caspase-1. Caspase-1 
converts pro-interleukin 1β to active IL-1β, a potent inducer of inflammation (51). 
   
Fas Deficient and Fas Knockout Mice 
Fas deficient mice have an interesting metabolic phenotype. Under chow diet these 
mice are heavier than their wildtype counterparts. However, they have less 
epididymal fat mass. Under high fat diet, Fas deficient mice increase their epididymal 
adipose tissue mass to the same extent as wild type mice. But the mean diameter of 
their fat cells does not increase, pointing towards hyperplasia of the tissue. Fas 
deficient mice show reduced macrophage infiltration into adipose tissues under high 
fat diet. Furthermore, Fas deficient mice are partly protected from high fat diet induce 
insulin resistance.   
Specific ablation of the Fas receptor in adipocytes also partly protects mice from high 
fat diet-induced insulin resistance. Under high fat diet these adipocyte specific Fas 
knockout (AFasKO) mice show a favourable inflammatory profile in adipose tissue 
and less hepatosteatosis as well as less ceramide accumulation in the liver. 
Protection from insulin resistance of the liver mainly due to reduced IL-6 production of 
adipose tissue is an explanation for the healthier metabolism of high fat diet fed 
AFasKO mice (for details see attached paper).   
Introduction – Aims of this Work 
Aims of this Work 
 
The data obtained from Fas deficient and Fas knockout mice suggest that Fas 
influences adipocyte physiology and plays a role in the development of high fat diet-
induced insulin resistance. We aimed to investigate the molecular mechanisms and 
consequences of Fas signalling in adipocytes by using the well established 3T3-L1 
preadipocyte cell line. Better understanding of the effects of Fas in adipocytes will 
help to understand the complex influence of Fas on whole body physiology in the 
context of obesity and insulin resistance. 
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Materials and Methods 
 
Cell Culture 
 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 25 
mM glucose (high glucose), fetal bovine serum and antibiotics. 48 hours after 
reaching confluence, cells were treated with a mixture of methylisobutylxanthine (500 
μM), dexamethasone (1 μM), insulin (1.7 μM) and rosiglitazone (1 μM) to induce 
differentiation (day 0, D0). Two days later (D2) the medium was changed to high 
glucose culture medium containing insulin (0.5 μM). Another 2 days later (D4) the 
medium was replaced with culture medium alone. The culture medium was replaced 
every other day and changed to culture medium containing 5.5 mM glucose (low 
glucose) after 4 days (D8). Cells were kept at least 2 days on low glucose before 
experiments with mature adipocytes were performed. Adipocytes were generally 
treated with 2 ng per ml FasL (Upstate, Lake Placid, NY, USA) in DMEM containing 
no FCS for the indicated time. 
 
 
Experiments in Preadipocytes 
 
Proliferation 
Cells were seeded in two different cells densities with the indicated amounts of FasL 
in the medium. Proliferation was assessed by measuring the reduction of MTT 
(Sigma) 48 hours after the cells were seeded and on D0. In living cells MTT is 
reduced in the mitochondria to the purple coloured formazan. Cells were washed 
twice with PBS and incubated in DMEM containing 0.5 mg MTT per ml for 1 hour. 
Thereafter cells were washed again twice with PBS and formazan was extracted with 
DMSO during 10 minutes. Absorption of the extracts was determined at 550 and 650 
nm and the lower reading (650 nm) was subtracted from the higher (550 nm). 
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Differentiation 
Cells were treated with different concentrations FasL per ml during different periods 
of differentiation and lipid accumulation was measured using Oil Red O staining as 
follows. At day 8 cells were fixed with 10% formalin, rinsed with 70% ethanol, 
incubated in Oil Red O solution and washed with H2O. Further, preadipocytes were 
treated with or without 2 ng/ml FasL and lysates were taken at different time points 
during differentiation. The differentiation markers pERK1/2, C/EBPα, C/EBPβ and 
PPARγ were analyzed on the protein level.  
 
 
Experiments in Mature Adipocytes 
 
Measurement of Lipolysis 
Mature adipocytes were incubated in DMEM containing no FCS with or without 2 
ng/ml FasL and the different compounds listed below for the indicated time periods. 
Thereafter, cells were washed with PBS and FFAs and glycerol were collected in 
Krebs-Ringer-HEPES buffer supplemented with 0.1% fatty acid free BSA for one 
hour. FFAs in the supernatant were measured with the NEFA kit from Wako (Neuss, 
Germany) and glycerol with the free glycerol reagent from Sigma.   
 
Measurement of Cytokine Secretion 
Cells were treated with 2 ng/ml FasL for the indicated time periods. Thereafter, cells 
were washed with PBS and cytokines were collected in Krebs-Ringer-HEPES buffer 
supplemented with 0.1% fatty acid free BSA for one hour. KC and IL-6 were 
measured with Luminex xMAP Technology. 
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Western Blotting 
Adipocytes were lysed in ice-cold lysis buffer containing 150 mM NaCl, 50 mM Tris-
HCl (pH 7.5), 1 mM EGTA, 1% NP-40, 0.25% sodium deoxycholate, 1 mM sodium 
vanadate, 1 mM NaF, 10 mM sodium β-glycerolphosphate, 100 nM okadaic acid, 0.2 
mM PMSF and a 1:1000 dilution of protease inhibitor cocktail (Sigma). Protein 
concentration was determined using a BCA assay (Pierce, Rockford, IL, USA). Equal 
amounts of protein were resolved by LDS-PAGE (4-12% gel; NuPAGE, Invitrogen, 
Basel, Switzerland) and electro-transferred onto nitrocellulose membranes (0.2 μm, 
BioRad, Reinach, Switzerland). Protein content on membranes was checked by 
Ponceau S staining. Blots were blocked in tris-buffered saline containing 0.1% Tween 
(TBS-T) supplemented with 5% non fat dry milk. Primary antibody was applied in the 
same buffer in a dilution of 1:1000, secondary antibody in a dilution of 1:5000. 
Primary antibodies against the following proteins were used: PPARγ, C/EBPα, 
C/EBPβ (Santa Cruz Biotechnology), phospho-ERK1/2, total ERK1/2, phospho-
STAT3 (Ser727) (from Cell Signaling Technology), Perilipin A (MBL International) 
and lipin-1 (Novus). Signal was generated based on chemoluminiscence and 
detected with the Fuji LAS-3000 image reader. 
 
RNA Extraction and Quantitative RT-PCR 
Total RNA was extracted using the NucleoSpin Kit (Macherey-Nagel, Oensingen, 
Switzerland). RNA was analyzed with a bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA), and concentration was determined with a nanodrop. 0.5 μg of RNA 
was reverse transcribed with Superscript III Reverse Transcriptase (Invitrogen) using 
random hexamer primer (Invitrogen). Taqman (Applied Biosystems, Rotkreuz, 
Switzerland) was used for real-time PCR amplification. All primers were purchased 
from Applied Biosystems: Lipin-1 (Mm01276800_m1), IL-6 (Mm00446190_m1), HSL 
(Mm00495359_m1), 36BA (Mm00725448_s1). 36BA (acidic ribosomal 
phosphoprotein) was used as housekeeping gen. The reaction mixture consisted of 2 
μl cDNA (diluted 1:5 after RT), 10 μl Master Mix (No AmpErase, Applied Biosystems), 
1 μl primer and 7 μl H20 to a final volume of 20 μl. The amplification protocol 
consisted of a 2 min period at 50° C to activate the Uracil-N-Glycosylase. Then, 
samples were heated to 95°C, followed by 40 cycles with denaturation at 95° C for 15 
sec and annealing/elongation at 60°C for 1 min (Applied Biosystems). Relative gene 
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expression was obtained after normalization to 18S RNA (Applied Biosystems), using 
the formula 2-∆∆cp (62). 
 
Measurement of CaMKII Activity 
Cells were treated with 2 ng/ml FasL or 5 nM TNFα for 6 hours or with 1 μM 
isoproterenol for half an hour. Additionally time course experiments were conducted 
with FasL treatment alone. Lysis was performed with a buffer that contained 50 mM 
HEPES, 1 mM EGTA, 10% glycerol, 1 mM sodium vanadate, 100 nM okadaic acid, 
0.2 mM PMSF and a 1:1000 dilution of protease inhibitor cocktail (Sigma P8340). To 
test the influence of the lysis conditions the lysis buffer used for Western blotting was 
used in one experiment. Enzyme activity was analysed with the CaMKII Assay 
System V8161 from Promega and radioactive [γ-32P]ATP from PerkinElmer. The 
assay uses a biotinylated substrate that is phosphorylated by CaMKII. Biotin is 
captured onto a streptavidin coated membrane. The radioactivity of the membrane 
measured in a β-counter corresponds to the activity of the enzyme. The assay was 
performed following the manufactures instructions. A buffer supplemented with 
calcium and calmodulin was used as positive control. 
 
MS Analysis of Phosphatidic Acid 
Cells were incubated with 2 ng/ml FasL or 5 nM TNFα for 6 hours and lysed with 
0.05 N NaOH. The PA fraction was extracted from 1 volume of lysate three times with 
one volume of butanol. Prior to analysis the extracts were buffered with 5 mM 
ammonium acetate and 1,2-Dioctanoyl-sn-glycerol 3-phosphate (Sigma) was added 
as internal standard. Masses were analyzed with a Q-Tof mass spectrometer in 
positive ion mode. Data were quantified using the MassLynx Software from Waters. 
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Compounds Used for Cell Treatment 
 
MEK1/2 Inhibitor 
The MEK1/2 inhibitor U0126 was purchased from Sigma (Buchs, Switzerland). 
Dilutions of a 50 mM stock solution in DMSO were used in the experiments. The 
inhibitor was added at the same time as FasL in a concentration of 50 μM. 
 
Recombinant KC 
Carrier free recombinant KC was bought from R&D Systems. The cytokine was 
dissolved in PBS containing 0.1% endotoxin free bovine serum albumin to form a 
stock solution with a concentration of 100 μg per ml. The cytokine was used in 
concentrations ranging from 0.1 to 100 ng per ml and for different time periods from 1 
hour to 9 hours. 
 
Inhibitors of IL-6 Signalling 
The IL-6 receptor superantagonist 7 (Sant7, sigma-tau) was stored as a 50 μg/ml 
stock in 0.9% NaCl. Sant7 was applied to the cells in concentrations ranging from 2 
ng to 2 μg per ml. The recombinant IL-6 antibody was from R&D Systems and a 
stock solution with a concentration of 100 μg per ml was prepared in PBS. The stock 
solution was dissolved to yield concentrations of 50, 500 and 5000 ng per ml in the 
culture medium. Inhibitors for the Janus protein tyrosine kinases (JAKs) were bought 
from Calbiochem.  Pyridone 6 was stored as a 10 mM stock solution in DMSO and 
was used in concentrations ranging from 1 nM to 1 μM. AG490 and WHI-P131 were 
dissolved in DMSO to form 100 mM DMSO stocks. Concentrations of both AG490 
and WHI-P131 in the culture medium were 10, 50 and 100 μM. When not stated 
differently, compounds were added to the cells at the same time as FasL.  
 
Rosiglitazone 
Rosiglitazone used for induction of differentiation and for treatment of mature 
adipocytes was from Alexis Biochemicals. The thiazolidinedione was stored as a 15 
mM stock solution in DMSO. Mature adipocytes were pretreated for 48 hours with 5 
μM of the compound. Thereafter FasL together with rosiglitazone was applied for 
another 12 hours.  
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Calcium Chelators and CaMKII Inhibitor 
The calcium chelator EDTA was used in dilutions from a 0.5 M stock solution in H2O. 
EDTA was applied to the cell culture medium in concentrations from 0.1 to 10 mM.  
The intracellular calcium chelator BAPTA/AM was purchased from Calbiochem and 
dissolved in DMSO to form a 50 mM stock. BAPTA/AM was used in concentrations of 
10 and 50 μM. KN62, an inhibitor of CaMKII was from Sigma and used in 0.1, 1 and 
10 μM dilutions from a 10 mM DMSO stock solution. Inhibitors were added to the 
cells at the same time as FasL. 
 
Phosphatidic Acid 
Phosphatidic acid (1,2-Dioctanoyl-sn-glycerol 3-phosphate) was purchased from 
Sigma. The compound was dissolved in sterile H2O. Dilutions of a 10 mM stock 
solution were used in the experiments. Adipocytes were incubated with 10, 50 or 100 
μM of PA for 3 hours. 
 
Data Analysis 
Data are presented as means ± SEM and if not stated differently were analyzed by 
one sample t test, *p < 0.5, **p < 0.01, #p < 0.001. 
Results 
Results 
 
Fas Expression in Preadipocytes and Adipocytes 
 
As shown in Fig. 1, Fas is expressed in 3T3-L1 preadipocytes, during adipocyte 
differentiation (D1, 2, 4 and 6) and in mature adipocytes. Expression levels of the 
adipocyte specific proteins PPARγ, C/EBPα and perilipin reflect the respective stage 
of differentiation. 
 
PreAC     D1      D2       D4      D6        AC  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 The Fas receptor is expressed in 3T3-L1 cells. Lysates of 3T3-L1 preadipocytes (PreAC, 
D0), differentiating (D1, 2, 4 and 6) and mature adipocytes (AC) were resolved by LDS-PAGE and 
immunoblotted with an antibody against the Fas receptor, PPARγ, C/EBPα, and perilipin. 
 
 
Influence of Fas on Preadipocytes 
 
Fas Reduces Proliferation of Preadipocytes 
In Fas deficient mice, adipocyte size did not increase under high fat-feeding, even 
though, epididymal adipose tissue mass increases to the same extent as in wild type 
mice. This indicates a hyperplastic adipose tissue response to a high fat diet in mice 
with Fas deficiency and an influence of Fas signalling on preadipocyte proliferation 
and differentiation. 
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Results 
Treatment of 3T3-L1 preadipocytes with FasL dose-dependently reduced MTT 
incorporation 48 hours after cells were seeded indicating that Fas inhibits the 
proliferation of these cells (Fig. 2). 
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Fig. 2. Fas activation reduces proliferation of preadipocytes. Preadipocytes were seeded in two 
cell densities of 50’000 cells per well (A) or 80’000 cells per well (B) and treated with the indicated 
concentrations of FasL. MTT reduction was measured 48 hours after cells were seeded or on D0. 
Results are means ± SEM from 2 to 3 wells from the same plate. 
 
Fas May Modulate Adipocyte Differentiation 
To investigate the influences of Fas on the molecular chain of events during 
adipocyte differentiation, protein levels of key markers of differentiation were 
analyzed. FasL treatment reduced the early induction of pERK1/2 (Fig. 3A). Such 
early activation of the MAP kinases is important for mitotic clonal expansion of the 
cells and, thus, for differentiation. Furthermore, FasL treatment reduced protein levels 
of the transcription factors C/EBPβ, C/EBPα and PPARγ (Fig. 3B). Moreover, in 
experiments culturing primary adipocytes from the stromal vascular fraction of 
adipocyte-specific Fas-knockout or wild-type mice we found a trend towards 
increased differentiation in Fas-deficient preadipocytes (data not shown). Overall, 
these experiments hint towards an inhibitory role of Fas on adipocyte differentiation. 
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Fig. 3. Fas reduces markers of differentiation in differentiating 3T3-L1 preadipocytes. Cells were 
seeded with 2 ng/ml FasL in the culture medium. 48 hours after cells reached confluence 
differentiation was induced with isobutylmethylxanthine (IBMX), dexamethasone, insulin and 
rosiglitazone. At the indicated time points after induction of differentiation protein expression was 
analyzed. Total cell lysates were resolved by LDS-PAGE and immunoblotted with anti-phospho-
ERK1/2 and total ERK (A), anti-C/EBPβ, anti-C/EBPα or anti-PPARγ (B) antibody. Results are the 
mean ± SEM of 2-3 independent experiments, *p < 0.5. 
 
 
Fas Activation Induces Lipolysis in Mature Adipocytes 
 
Fas-Induced Lipolysis is ERK1/2-Dependent 
As described in the Introduction, total body and adipocyte-specific Fas-knockout mice 
were partly protected from high fat diet-induced adipocyte insulin resistance. 
Therefore, we intended to explore the effect of Fas stimulation on glucose uptake 
and lipolysis in adipocytes in culture. We previously observed that Fas activation 
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Results 
increased basal and decreased insulin-stimulated glucose uptake in 3T3-L1 
adipocytes. 
Furthermore, incubation of adipocytes with FasL regulated lipolysis in a time-
dependent manner with an initial decrease after 2 hours and a significant increase 
after 6 to 12 hours (Fig. 4).  
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Fig. 4. FasL treatment induces lipolysis in 3T3-L1 adipocytes. Cells were incubated with FasL for 
the indicated time periods. Free fatty acid (A) and glycerol release (B) was determined after medium 
was removed and cells were incubated with KREBS buffer for another hour. Results represent the 
mean ± SEM of 5 (A) or 4 (B) independent experiments, *p < 0.5, **p < 0.01. 
 
Like the TNF receptors, Fas belongs to the tumour necrosis receptor superfamily. 
TNFα was previously shown to induce lipolysis in 3T3-L1 cells via activation of the 
p44/42 MAP kinases (ERK1/2) (32), we therefore postulated that FasL-induced 
lipolysis is similarly dependent ERK1/2 activation. Incubation of mature 3T3-L1 
adipocytes with 2 ng/ml FasL increased phosphorylation of ERK1/2 with a first peak 
after 15 minutes and a second, even higher peak after 6 hours (Fig. 5). 
Phosphorylation was still significantly increased after 12 hours of treatment. Total 
protein concentration of ERK1/2 was not affected by the treatment. 
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Fig. 5. FasL activates ERK1/2. Mature 3T3-L1 adipocytes were incubated with 2 ng per ml FasL for 
the indicated time periods. Total cell lysates were resolved by LDS-PAGE and immunoblotted with 
anti-phospho-ERK1/2 or anti-ERK1/2 antibodies. Results are the mean ± SEM of 6-10 independent 
experiments, *p < 0.5, **p < 0.01, #p < 0.001. 
 
To assess whether Fas-stimulated lipolysis is dependent on ERK1/2 activation, we 
incubated 3T3-L1 cells in presence or absence of the MEK inhibitor U0126. U0126 
inhibited Fas-induced ERK1/2 phosphorylation dose-dependently. In a concentration 
of 50 μM U0126 reduced the enzyme’s activity to the level in the control (Fig. 6A). 
lnhibition of the MAP kinase pathway completely blocked Fas-induced lipolysis (Fig. 
6B). Thus, Fas-stimulated lipolysis is dependent on ERK1/2 activation. 
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Fig. 6. Fas-induced lipolysis is dependent on ERK1/2 activation. 3T3-L1 adipocytes were treated 
with FasL and different concentrations of the MEK inhibitor U0126. Western blot analysis was 
performed with an antibody against pERK1/2 (A). Cells were incubated with or without FasL and 50 
μM of U0126 for 12 hours. Glycerol release was determined after medium was removed and cells 
were incubated with KREBS buffer for another hour. Results are the mean ± SEM of 3 - 6 independent 
experiments, *p < 0.5, #p < 0.001. 
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Pretreatment with Rosiglitazone Partly Reverses FasL-Induced Lipolysis 
As shown in preadipocytes, 12 hours of FasL treatment significantly down-regulated 
C/EBPα and PPARγ content in mature 3T3-L1 adipocytes (Fig. 7) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. FasL treatment down-regulates adipogenic markers in mature adipocytes. 3T3-L1 
adipocytes were subjected to FasL treatment for 12 hours. Western blot analysis was performed with 
an antibodies against C/EBPα and PPARγ. The graphs show the mean ± SEM of 4 (C/EBPα) or 5 
(PPARγ) independent experiments, **p < 0.01, #p < 0.001. 
 
To test whether PPARγ activation modulates the effects of Fas activation, 3T3-L1 
adipocytes were pre-treated with the PPARγ ligand rosiglitazone. Importantly, 
rosiglitazone pre-treatment reduced FasL-stimulated ERK1/2 phosphorylation without 
affecting total ERK1/2 protein content (Fig. 8).  
 
 
 
 
 
 
 
 
 
 
Fig. 8. Rosiglitazone pretreatment reduces Fas-induced ERK1/2 phosphorylation. Cells were 
incubated with or without 5 μM rosiglitazone for 60 hours. During the last 6 or 12 hours of this 
incubation period cells were treated with FasL. Total cell lysates were resolved by LDS-PAGE and 
immunoblotted with anti-phospho-ERK1/2 or anti-ERK1/2 antibodies. Results are the mean ± SEM of 
4 independent experiments, *p < 0.5, **p < 0.01 (Student’s t test). 
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Results 
Moreover, pre-treatment with rosiglitazone also reduced FasL-mediated lipolysis (Fig. 
9). Thus, these sets of experiments further confirmed the importance of ERK-
activation for FasL-induced lipolysis.  
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Fig. 9. Rosiglitazone reduces Fas-induced lipolysis. Cells were incubated with or without 5 μM 
rosiglitazone for 60 hours. During the last 12 hours of this incubation period cells were treated with 
FasL. Glycerol release was determined after medium was removed and cells were incubated with 
KREBS buffer for another hour. Results are the mean ± SEM of 4 independent experiments, *p < 0.5, 
ns: not significant. 
 
 
Potential Downstream Effects of FasL-Induced ERK1/2 Activation 
 
Fas Reduces Perilipin and HSL 
So far we could demonstrate that FasL-induced lipolysis is dependent on the  
activation of the ERK1/2 MAP kinases. 
The lipid droplet coating protein perilipin and the lipase HSL play an important role in 
lipolysis (30). Gene expression of both perilipin and HSL are regulated by PPARγ 
(63,64). Furthermore, MAP kinase-mediated serine phosphorylation of PPARγ was 
shown to reduce its activity (65). Interestingly, TNFα-induced lipolysis is associated 
with ERK1/2-dependent down-regulation of perilipin (32). Thus we postulated that 
FasL treatment may as well decrease expression of perilipin. Indeed, we found that 
FasL treatment also reduced perilipin protein content in adipocytes. Inhibition of 
ERK1/2 activation, however, could not rescue FasL-mediated decrease of perilipin 
content (Fig. 10A) whereas it prevented FasL-induced lipolysis as shown above (Fig. 
6B). Therefore, the latter does not seem to be dependent on FasL-mediated 
reduction of perilipin. 
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Surprisingly, FasL treatment also decreased HSL mRNA, which is an important 
enzyme in the breakdown of triacylglycerols (Fig. 10B). Although activity of HSL is 
regulated through phosphorylation (30), we hypothesized that the Fas-induced 
increase in lipolysis would be mirrored by an increased expression of the lipase. HSL 
was shown to be activated by ERK1/2 through phosphorylation on serine 600 (66). 
Since there is no commercial antibody available against this specific form of HSL, we 
have no state anything about the activity of the enzyme after FasL treatment. 
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Fig. 10. Activation of Fas down-regulates perilipin and HSL. Cells were incubated for the indicated 
time periods with or without FasL (2 ng/ml) and the MEK inhibitor U0126. Perilipin protein levels in 
whole cell lysate were analyzed by Western blot analysis (A). Real-time PCR was performed to 
determine HSL mRNA levels (B). Results are the mean ± SEM of 3 (A) and 2 (B) independent 
experiments, *p < 0.5, **p < 0.01, ns: not significant. 
 
 
Potential Upstream Mediators of FasL-Induced ERK1/2 Activation 
 
Phosphatidic Acid 
Interestingly, we found that Fas activation decreases both mRNA and protein levels 
of lipin-1 (Fig. 11). Lipin-1 is a phosphatase involved in the formation of 
triacylglycerols from glycerol-3-phosphate.  Reduced lipin-1 protein levels could not 
be rescued through inhibition of the MAP kinase pathway either (Fig. 11B).  
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Results 
Suggesting that FasL-induced downregulation of lipin is either ERK-independent or 
upstream of ERK-activation. 
 
 A B
 
 
 
 
Fig. 11. Fas activation down-regulates lipin-1. Cells were incubated for the indicated time periods 
with or without FasL (2 ng/ml) and the MEK inhibitor U0126. Real-time PCR was performed to 
determine lipin-1 mRNA levels (A). Lipin-1 protein levels in whole cell lysate were analyzed by 
Western blot analysis (B). Results are the mean ± SEM of 4 independent experiments, *p < 0.5, **p < 
0.01, #p < 0.001. 
 
Lipin-1 deficiency in mice was shown to lead to the accumulation of its PA acid WAT. 
Further PA can induce ERK1/2 (25). In order to test whether PA could be responsible 
for FasL-induced ERK1/2 activation and lipolysis, 3T3-L1 adipocytes were incubated 
with varying concentrations of PA for different time periods. Addition of 100 μM PA 
for 3 hours to 3T3-L1 activated ERK1/2 without effecting total ERK1/2 content (Fig. 
12A). Moreover, incubation with PA for the same time period induced lipolysis, and 
this effect was prevented through inhibition of the MAP kinase pathway (Fig. 12B). 
Thus, PA induces lipolysis in 3T3-L1 adipocytes in an ERK1/2-dependent manner. 
 
 
 
 
 
 
0 0.5 1 6 9
0.0
0.2
0.4
0.6
0.8
1.0
1.2
*
**
*
#
2 ng/ml FasL [h]
Li
pi
n-
1 
/ 3
6B
4 
m
R
N
A
(fo
ld
 o
f c
on
tr
ol
)
0 6 12
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Co
U0126
*
* ** *
2ng/ml FasL [h]
Li
pi
n-
1 
(fo
ld
 o
f b
as
al
)
FasL [h] 
U0126 
0       6      12       0        6      12     
Lipin-1 
 38
Results 
 
 
A                                                                    B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. Phosphatidic acid induces ERK1/2-dependent lipolysis. Cells were incubated with 
different concentrations of PA for 3 hours. Total cell lysates were resolved by LDS-PAGE and 
immunoblotted with antibodies against phospho-ERK1/2 and total ERK (A). Adipocytes were 
incubated with or without 100 μM PA and the MEK inhibitor U0126 for 3 hours. Glycerol release was 
determined after medium was removed and cells were incubated with KREBS buffer for another hour 
(B). Results are the mean ± SEM of 5 (A) or 4 (B) independent experiments, *p < 0.5, **p < 0.01, ns: 
not significant. 
 
As a next step, we measure PA concentration in 3T3-L1 adipocytes using MS. Given 
the above results, we expected that incubation with FasL would increase PA 
concentration. However, we could not detect any differences in PA concentrations 
(Fig. 13), suggesting either that FasL treatment does not increase PA concentration 
or that we were not able to detect such potential difference. 
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Fig. 13. Fas activation does not lead to phosphatidic acid accumulation. 3T3-L1 adipocytes were 
incubated with 2 ng per ml FasL or 5 nM of TNFα for 6 hours. Cells were lysed with 0.05 N NaOH and 
PA species were extracted with butanol and quantified using MS. Results are the mean ± SEM of 6 or 
3 (18:0/18:1) independent experiments. 
  
Calcium Signalling 
Changes in intracellular calcium (Ca) concentrations are a hallmark of a broad range 
of signalling pathways such as muscle contraction, exocytosis and apoptosis. 
Increased Ca can lead to downstream signalling effects through binding to 
calmodulin (CaM). CaM binds 4 calcium ions but has no intrinsic enzymatic activity. 
By complex formation with many different enzymes CaM renders their activity Ca 
dependent. One of these enzymes is the calcium/calmodulin dependent protein 
kinase II (CaMKII). CaMKII was shown to mediate magnolol-triggered lipolysis in 
sterol ester-loaded 3T3-L1 preadipocytes in an ERK1/2 dependent fashion (67). We 
therefore postulated that FasL-induced lipolysis may be dependent on intracellular 
changes in Ca levels. As an initial experiment, we tested whether the extracellular Ca 
chelator EDTA was able to reduced Fas induced-ERK1/2 activation and lipolysis. 
Indeed preincubation with EDTA prevented both FasL-induced ERK-activation and 
lipolysis (Fig. 14). 
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Fig. 14. EDTA reduces Fas-induced pERK1/2 and lipolysis. 3T3-L1 adipocytes were incubated with 
or without FasL and different concentrations of EDTA for 12 hours. Phosphorylated ERK1/2 was 
measured in whole cell lysate by Western blot analysis (A). Glycerol release was determined after 
medium was removed and cells were incubated with KREBS buffer for another hour (B). Results are 
the mean ± SEM of 4 independent experiments, *p < 0.5, **p < 0.01, #p < 0.001, ns: not significant (1 
and 10 mM EDTA cond.: Student’s t test). 
 
However, EDTA is an unspecific Ca chelator and the effective concentrations were 
toxic to the cells. Thus we applied the intracellular Ca chelator BAPTA/AM to 3T3-L1 
adipocytes. BAPTA/AM treatment mimicked the effects of EDTA without toxicity as 
depicted in Fig. 15.  
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Fig. 15. BAPTA/AM reduces Fas-induced pERK1/2 and lipolysis. 3T3-L1 adipocytes were 
incubated with or without FasL and different concentrations of BAPTA/AM for 12 hours. 
Phosphorylated ERK1/2 was measured in whole cell lysate by Western blot analysis (A). Glycerol 
release was determined after medium was removed and cells were incubated with KREBS buffer for 
another hour (B). Results are the mean ± SEM of 4 (A) or 3 (B) independent experiments, *p < 0.5. 
 
Moreover, the CaMKII inhibitor KN62 reduced FasL-mediated ERK1/2 activation as 
well as lipolysis suggesting the involvement of CaMKII-activation (Fig. 16).  
 
 A                                                                 B 
 
 
 
 
Fig. 16. The CaMKII inhibitor KN62 reduces Fas-induced pERK1/2 and lipolysis. 3T3-L1 
adipocytes were incubated with or without FasL and different concentrations of the CaMKII inhibitor 
KN62 for 12 hours. Phosphorylated ERK1/2 was measured in whole cell lysate by Western blot 
analysis (A). Glycerol release was determined after medium was removed and cells were incubated 
with KREBS buffer for another hour. Results are the mean ± SEM of 4 (A) and 5 (B) independent 
experiments, *p < 0.5, **p < 0.01 (KN62 conditions (B): Student’s t test). 
 
Consequently, CaMKII activity was measured in the presence or absence of FasL 
treatment. As a control, we also looked at the ability other lipolytic compounds such 
as TNFα and isoproterenol to induce CaMKII activity. Neither pre-treatment with 
FasL nor with TNFα stimulated CaMKII activity (Fig. 17). Surprisingly, short-term 
treatment with isoproterenol activated CaMKII significantly. Use of a different lysis 
buffer yielded exactly the same result for 6 hours Fas and TNFα or 0.5 hour 
isoproterenol treatment. 
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Fig. 17. Fas treatment does not induce CaMKII activation. Cells were incubated with 2 ng/ml FasL 
for different time periods, with 5 nM TNFα for 6 hours or with 1 μM isoproterenol for 30 minutes. 
Thereafter, CaMKII activity was measured. As positive control a buffer containing Ca and calmodulin 
was used. Results are the mean ± SEM of 2 to 8 independent experiments, *p < 0.5, #p < 0.001. 
 
Hence, Ca signalling may meditate the lipolytic effect of FasL treatment. The lack in 
CaMKII activation after FasL-treatment though speaks against an involvement of the 
latter enzyme. 
 
Cytokine Signalling 
Adipocyte-specific Fas-knockout mice were protected from high fat diet-induced 
insulin resistance and this was associated with reduced adipose tissue inflammation 
as reflected by reduced macrophage infiltration, decreased expression of pro-
inflammatory cytokines (IL-6, IL-1beta) and increased expression anti-inflammatory 
cytokines (IL-10). We thus hypothesized that Fas-activation increases the expression 
and/or secretion of pro-inflammatory cytokines. 3T3-L1 adipocytes were treated with 
FasL and cytokine secretion into the supernatant was determined. As expected, Fas 
activation increased the secretion of the chemokine KC (mouse homologue of IL-8) 
(2.5 fold, Fig. 18A) and of the cytokine IL-6 (1.5 fold, Fig. 18B), whereas TNFα was 
not detectable (data not shown), Consistent with an increased secretion, FasL 
induced IL-6 mRNA expression in a time-dependent manner (Fig. 18C). Furthermore, 
FasL treatment increased the phosphorylation of STAT3 (Fig. 18D). STAT3 is a 
component of the JAK-STAT signalling pathway that is activated by various 
cytokines, and IL-6 is a known inducer of this STAT isoform.  
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Fig. 18. FasL induces KC and IL-6 secretion, IL-6 mRNA expression and pSTAT3. Adipocytes 
were incubated with FasL for the indicated time periods. Cytokine release was determined after 
medium was removed and cells were incubated with KREBS buffer for another hour (A, B). Real-time 
PCR was used to determine mRNA expression of IL-6 (C). Cells were treated for 6 hours with FasL 
and the amount of pSTAT3 in whole cell lysates was analyzed by Western blot (D). Results are the 
mean ± SEM of 4 (A), 3 - 5 (B), 2 (C) or 4 (D) independent experiments, *p < 0.5, **p < 0.01. 
 
IL-6 was previously shown to induced lipolysis (33). Since FasL treatment increased 
IL-6 expression, secretion and phosphorylation of STAT3, we postulated that FasL 
treatment may induce lipolysis via IL-6 secretion in a paracrine manner. To test this 
hypothesis FasL-treated 3T3-L1 adipocytes were incubated in the presence of the IL-
6 receptor superantagonist 7 (Sant7). Sant7 is a modified IL-6 molecule that binds to 
the IL-6 receptor but does not induce signalling. Surprisingly, Sant7 did not reduce 
Fas-mediated phosphorylation of STAT3 (Fig. 19). On the other hand Sant7 
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significantly reduced the phosphorylation of ERK1/2 (Fig. 19). However, the amount 
of inhibition varied considerably between individual experiments.  
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Fig. 19. Sant7 does not affect Fas-induced pSTAT3 but down-regulates pERK1/2. Adipocytes 
were treated with FasL and with or without Sant7 for 6 hours. Amounts of pSTAT3 and pERK1/2 in 
whole cell lysates were quantified by Western blot analysis. Results are the mean ± SEM of 6 
independent experiments, **p < 0.01. 
 
To further clarify the participation of the IL-6 signalling pathway in Fas-induced 
lipolysis adipocytes were incubated with JAK inhibitors or a neutralising IL-6 antibody 
during FasL treatment. Disappointingly, treatment with the JAK2 inhibitor AG490 as 
well as with the JAK3 inhibitor WHI-P131 did not reduce FasL-induced 
phosphorylation of ERK1/2 and STAT3 (Fig. 20A). The pan-JAK inhibitor P6 had no 
significant effect on FasL-induced phosphorylation of ERK1/2 although it partly 
reduced pSTAT3 (Fig. 20B). In addition, ERK1/2 phosphorylation could not be 
reduced in the presence of neutralising IL-6 antibody, not even at very high 
concentrations (Fig. 20C).  
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Fig. 20. Treatment with JAK inhibitors or an IL-6 antibody does not reduce Fas-induced 
phosphorylation of ERK1/2. Adipocytes were treated for 6 hours with FasL and with or without 
different concentrations of the JAK inhibitors AG490 (JAK2), WHI-P131 (JAK3) (A) and P6 (pan-JAK, 
B) or an IL-6 antibody (C). Amounts of pERK1/2 and pSTAT3 in whole cell lysates were quantified by 
Western blot analysis. Results for the experiments with P6 are the mean ± SEM of 2, 4 (100 nM) or 8 
(10 nM) independent experiments, **p < 0.01. 
 
These results suggest that increase in IL-6 secretion does not contribute to FasL-
induced lipolysis, at least not to a significant extent. 
Both TNFα and IL-6 are described to have lipolytic activity but could be excluded in 
our context. As we also measured increased KC secretion after FasL treatment and 
found no literature on a possible lipolytic action of the cytokine, we hypothesized that 
KC might induce lipolysis. 3T3-L1 adipocytes were treated with increasing dose of 
recombinant KC. However, as indicated in Fig. 21 no changes in glycerol release 
could be demonstrated.  
 
 
 
0 1 3 10 30 50
1.2
**
P6 [nM]
pS
TA
T3
 (S
er
72
7)
(fo
ld
 o
f F
as
L 
st
im
ul
at
ed
 c
on
tr
ol
)
10
0
25
0
50
0
10
00
C 
1 h before end of the experiment 
IL-6 AB [ng/ml] 0          50       500      5000       0          50       500     5000        
pERK1/2 
pSTAT3 
 46
Results 
 
 
A                                                                 B 
 47
 
 
 
 
 
 
 
 
Fig. 21. Recombinant KC does not increase lipolysis in 3T3-L1 adipocytes. Adipocytes were 
treated with different concentrations of recombinant KC (A) or with 100 ng/ml KC for the indicated time 
periods (B). Glycerol release was determined after medium was removed and cells were incubated 
with KREBS buffer for another hour. Results are the mean ± SEM of 4 (A) or 2 (B) independent 
experiments. 
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The term apoptosis is used in Greek to describe the falling of leaves from a tree. 
Working on the signalling of the Fas receptor, a well established inducer of apoptosis, 
has made it always difficult to determine which leaves are still green, swinging on the 
branches and which are dancing with the wind in orange and maroon on their way to 
the floor. As the induction of apoptosis results from a shift in the balance of survival 
and death signals to the latter, it was always hard to say which of the observed 
effects are due to cell death, proceed or even counteract it, or are of the kind that 
may be classified as non-apoptotic effects of the Fas receptor. 
The aim of the current work was to elucidate the impact of Fas signalling on 
adipocyte physiology based on the fact that Fas deficient mice and AFasKO mice 
have an improved metabolic profile when fed a high fat diet. 
 
The Fas receptor is expressed in 3T3-L1 preadipocytes, differentiating 3T3-L1 
preadipocytes and mature 3T3-L1 adipocytes (Fig. 1). Initial experiments were 
performed to investigate the possible role of the Fas receptor in preadipocyte 
proliferation and differentiation. Effects on morphological features like cell size and 
lipid loading as well as the influence on cell number and proliferation were taken into 
account. Furthermore, the impact of Fas on the expression of adipogenic markers 
was analyzed during differentiation. Activation of the Fas receptor leads to reduced 
proliferation of 3T3-L1 preadipocytes after 48 hours of incubation (Fig. 2). The 
increased MTT metabolism at D0 in FasL treated cells can be explained as follows. 
The control cells are confluent at this time point and undergo growth arrest, whereas 
Fas treatment led to a reduction in cell number and consequently prolonged the 
period of cell division. 
During differentiation, FasL inhibits the expression of adipogenic markers (Fig. 3). 
Longer incubation periods with FasL lead to cells loss and thereby less differentiated, 
lipid-filled adipocytes. Although some of the remaining differentiated adipocytes after 
FasL treatment seemed to be enlarged, a clear influence of Fas on morphological 
features of preadipocytes and adipocytes could not be demonstrated (data not 
shown). These results suggest that during high fat feeding of mice activation of Fas 
would act as a negative signal that inhibits the generation of new adipocytes and 
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thereby would favour the development of a more hyperplastic tissue. Lack of the Fas 
receptor on the other hand would lead to more adipocytes and a WAT that more 
efficiently stores excess energy. This concept seems to be verified when looking at 
Fas deficient mice which exhibit the same weight gain but smaller adipocytes. 
However, AFasKO mice show not difference in cellularity of WAT compared to wild 
type mice on a high fat diet. In AFasKO mice the Cre recombinase is driven by the 
fatty acid binding protein 4 (Fabp4) promotor. Since Fabp4 is downstream of PPARγ, 
Fas receptor expression is not down-regulated until during adipocyte differentiation in 
AFasKO mice. Thus, early adipocyte-development is unlikely to be affected in 
AFasKo mice, as opposed to Fas deficient mice. The reduction of preadipocyte 
proliferation as well as the reduction of differentiation markers and differentiated 
adipocytes in culture is most probably due to the apoptotic effect of Fas activation. It 
is however difficult to say if such an apoptotic effect on preadipocytes is present and 
as pronounced in vivo. 
 
In mature 3T3-L1 adipocytes, activation of the Fas receptor influences fuel 
metabolism in two major aspects. First, we previously observed that Fas induces 
basal glucose uptake and diminishes insulin stimulated glucose uptake. Second, Fas 
stimulation has a time dependent influence on lipolysis and prolonged activation of 
Fas leads to increased release of FFAs and glycerol (Fig. 4). The time course of 
FFAs and glycerol release completely match each other, which indicates that the 
increased of these two metabolites in the buffer is not due to cell leakage.  
ERK1/2 phosphorylation is induced by Fas stimulation (Fig. 5). After 15 minutes of 
FasL treatment the MAP kinases were induced significantly. After 30 minutes there 
was no difference compared to the control condition. After 3, 6 and 12 hours the 
kinases were again significantly activated. The shape of the graph suggests a kinetic 
with an acute less pronounced activation followed by a more pronounced activation 
after longer incubation periods. However, the little number of time points does not 
allow to eliminate the idea that pERK1/2 is increased gradually. In the case of a 
biphasic activation, we speculated that the activation seen after 15 minutes would be 
directly mediated by the Fas receptor whereas the activation induced after hours of 
incubation would be due to an indirect effect of Fas signalling. Although the signal for 
pERK1/2 is lower after 12 hours we can not conclude from the available data that 
ERK1/2 activation is again decreased gradually after 6 hours of incubation. In this 
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context, it is important to note that prolonged ERK1/2 activation can be linked to cell 
death (68). However, studies that link ERK1/2 activation to Fas triggered apoptosis 
show an acute and transient stimulation of the kinases (69,70). 
The ERK1/2 kinases are activated by a myriad of factors. Among those are the 
lipolytic cytokines IL-6 and TNFα as well as the chemokine IL-8. The TNF receptors 
(TNF-R) belong to the same receptor superfamily as Fas. TNFα stimulates lipolysis 
through activation of the TNF-R1 and this effect is completely dependent on the 
activity of ERK1/2 (32,34,71). Indeed, Fas induced lipolysis could also be inhibited by 
using the MEK inhibitor U0126 (Fig. 6). This ERK1/2 dependency was further 
underscored by the fact the rosiglitazone pretreatment inhibited both Fas-induced 
ERK1/2 activation and lipolysis (Fig. 8 and 9). Since FasL treatment did not increase 
TNFα secretion we can conclude that the lipolytic effect of FasL is not induced 
indirectly through TNFα.  
The glycerol assay we used also measures free glycerol-3-phosphate. As a 
consequence we first could not exclude the possibility that we measured a decrease 
in triacylglycerol synthesis instead of an increase in lipolysis. The ERK1/2 
dependency of Fas induced glycerol release further supports the notion that an 
increase in lipolysis was actually measured. 
In conclusion, prolonged Fas activation leads to an increase in lipolysis which is 
completely dependent on the activity of the ERK1/2 MAP kinases. 
Interestingly, incubation for 2 hours with FasL resulted in a significant decrease of 
FFAs and glycerol release (Fig. 4). Looking at the graph of ERK1/2 activity makes 
room for the assumption that the kinases are activated at this time point. We aimed to 
clarify this conflicting result. However, work on the small decrease in lipolysis 
obviously requires a high number of experiments to get significant results and initial 
trials with the MEK inhibitor led to no conclusion. Therefore we focused on the 
mechanisms behind the stimulation of lipolysis by FasL. 
 
We first aimed to investigate possible downstream consequences of the observed 
MAP kinase activation after FasL treatment. Like during preadipocyte differentiation 
Fas activation in mature adipocytes was associated with the down-regulation of the 
adipogenic markers C/EBPα and PPARγ (Fig. 7). This effect was very pronounced in 
the case of PPARγ which was reduced by 90 percent on the protein level after 12 
hours of FasL incubation. Consistent with this the PPARγ targets perilipin and HSL 
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(63,64) were also found to be reduced (Fig. 10). MAP kinase-mediated serine 
phosphorylation of PPARγ was shown to reduce the activity of the transcriptional 
factor (65). Since PPARγ and C/EBPα positively regulate each others expression 
(10), a MAP kinase-induce reduction in PPARγ activity may also effect its expression.  
Furthermore, TNFα-induced lipolysis was shown to involve ERK1/2-dependent 
reduction of the lipid droplet coating protein perilipin (32). We therefore postulated 
that the Fas mediated reduction of PPARγ  and perilipin are downstream effects of 
ERK1/2 activation. However, the increased activity of ERK1/2 induced by FasL 
treatment is not responsible for the reduction of PPARγ (data not shown) and perilipin 
(Fig. 10A). Nevertheless, the Fas-induced reduction of perilipin might facilitate 
triacylglycerol breakdown caused through ERK1/2 activation. The latter finding also 
suggests that Fas and TNF-R1 activation induce the same metabolic effect via 
different cellular mechanisms. In the context of increased lipolysis, FasL mediated 
reduction of HSL was a surprising finding. However, TNFα as well reduces the 
activity of HSL through inhibition of the enzyme’s gene expression in 3T3-L1 
adipocytes (72). On the other hand HSL can be activated by ERK1/2 through 
phosphorylation on serine 600 (66). But it is hard to hypothesize that Fas reduces the 
transcription of HSL like TNFα does but has the opposite effect when it comes to the 
enzyme’s activity. Thus, it remains to be proven which lipase is responsible for the 
breakdown of triacylglycerols after Fas (and TNF-R1) activation. 
 Besides the down-regulation of perilipin and HSL we also found lipin-1 (Fig. 11) to be 
reduced on mRNA and protein level after FasL treatment. Lipin-1 received much 
attention during the last years. In adipocytes this protein acts as a phosphatase in the 
process of triacylglycerol synthesis as well as a transcription factor (22). Moreover, 
lipin-1 acts as a transcriptional co-activator involved in the maturation and 
maintenance of adipocytes. Transcription of lipin-1 is induced by C/EBPα. By binding 
to PPARγ lipin-1 increases the positive transcriptional feedback loop between 
C/EBPα and PPARγ (23). It is therefore not surprising that the Fas induced down-
regulation of C/EBPα leads to a reduction of the lipin-1 transcript. The finding that 
ERK1/2 inhibition does not rescue the expression of lipin-1 (Fig. 11) suggests that 
ERK1/2 activation is not the cause but could rather be a downstream effect of Fas-
mediated lipin-1 reduction. In this case again TNFα has a similar effect. TNFα inhibits 
transcription of lipin-1 and this seems to be mediated via JAK2 (73). Since TNFα 
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does not directly signal via JAK2 the finding suggests an inflammatory 
autocrine/paracrine effect of TNFα treatment. As described later in more detail, the 
same JAK2 inhibitor previously used in the TNFα study (73) did not influence Fas 
induced phosphorylation of ERK1/2 nor did it rescue Fas-induced lipin-1 protein 
reduction (data not shown). Hence, TNFα is claimed to reduce perilipin via ERK1/2 
and to reduce lipin-1 in a JAK2 dependent but ERK1/2 independent fashion. Both 
signalling mechanisms seem not to be shared by the Fas receptor. 
A lack of lipin-1 in WAT was shown to lead to accumulation of its substrate PA which 
is another inducer of the MAP kinase pathway (25). Because of the latter findings we 
tested the impact of PA on 3T3-L1 adipocytes. Indeed, PA induced lipolysis in 
adipocytes and this effect was ERK1/2-dependent (Fig. 12). It is an interesting and 
novel finding that this intermediate of the triacylglycerol synthesis pathway is able to 
enhance the breakdown of triacylglycerols. In order to measure changes in cellular 
PA concentrations, MS analysis was applied. So far, we have not been able to detect 
any increase of intracellular PA after FasL treatment so far (Fig. 13). This could be 
due to inappropriate extraction of PA species in our approach with butanol as a 
solvent. Furthermore, spatial changes in intracellular PA concentration may have an 
important impact which cannot be detected by our approach. Analysis with a different 
extraction protocol is still ongoing at the time of writing this manuscript.  
Our group has previously shown that FasL treatment of 3T3-L1 adipocytes leads to 
the cleavage of PARP, a caspase substrate. Caspases also activate nucleases that 
degrade nuclear material and proteases that break-down nuclear and cytoskeletal 
proteins. In this context we found the transcript of AKT2 to be down-regulated by Fas 
treatment (data not shown). AKT is an important mediator of cell-survival signalling 
(74). Furthermore, PPARγ, perilipin, lipin-1 and HSL were all regulated on the 
transcriptional level. Based on the latter findings the reduction of the mentioned 
proteins could be explained by caspase-dependent DNA fragmentation which leads 
to reduced transcription of the respective genes. However, caspase inhibition could 
not correct the Fas-mediated effects on insulin stimulated glucose uptake and 
lipolysis (data not shown). 
To summarize, we found that Fas activation leads to the down-regulation of PPARγ, 
C/EBPα, perilipin, lipin-1 and HSL in mature adipocytes. Perilipin and lipin-1 are 
ERK1/2 independently regulated and in a different fashion than by TNFα. If the 
down-regulation of these proteins has a causative metabolic link to the Fas-induced 
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increase in lipolysis and if it has to be attributed to apoptosis could not definitely be 
answered. Experiments with caspase inhibitors suggest that the FasL-induced 
alterations in glucose and lipid metabolism are caspase-independently regulated 
whereas the induction of apoptosis is caspase-dependent.  
 
Secondly, we wanted to look for possible upstream mediators of the Fas-induced 
ERK1/2 activation. Intracellular calcium concentrations were reported to have 
different impacts on lipolysis. In human adipocytes that were differentiated in vitro 
increased intracellular calcium were found to decrease lipolysis through activation of 
PDE with a subsequent decrease in cAMP and HSL phosphorylation (35). The 
compound magnolol on the other hand was shown to induce lipolysis in sterol ester-
loaded 3T3-L1 preadipocytes through CaMKII dependent ERK1/2 activation (67). 
Chelation of extra- and intracellular calcium indicated a role for calcium fluxes in 
FasL-mediated lipolysis (Fig. 14 and 15). However, we obtained conflicting results 
regarding the involvement of CaMKII activation. Application of the CaMKII inhibitor 
KN62 during FasL treatment reduced ERK1/2 activation and lipolysis (Fig. 16). 
Analysis of CaMKII activity on the contrary revealed that neither FasL nor TNFα 
stimulated the enzyme (Fig. 17). Because of the higher specificity of the activity 
assay and the only partial effects of the inhibitor it is appropriate to conclude that a 
probable calcium mediated signal is transduced via another enzyme than CaMKII. 
Western blot analysis revealed that Fas stimulates PKC phosphorylation in a manner 
that is unlikely to be responsible for the increase in lipolysis (data not shown). Hence, 
which downstream effectors are activated by calcium in the signalling pathway(s) 
leading to Fas-induced lipolysis remains elusive. Considering calcium to be involved 
in this metabolic change triggered by the Fas receptor one is obliged to acknowledge 
that calcium is involved in multiple steps of the apoptotic process (75). Based on the 
findings mentioned above we can not exclude that apoptosis linked calcium fluxes 
are responsible for at least part of the lipolytic effect of FasL treatment. 
 
Fas activation increased the secretion of KC (mouse homologue to IL-8) and it 
induced IL-6 gene expression and secretion. Furthermore, it increased the 
phosphorylation of STAT3 (Fig. 18D). However, we could not show an influence of 
KC on lipolysis in 3T3-L1 adipocytes (Fig. 21). The cytokine IL-6 on the other hand is 
a known to induce lipolysis and STAT3 is a component of the IL-6 signalling cascade. 
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The increased IL-6 mRNA expression and IL-6 secretion (Fig. 18B and C) made it 
even more tempting to speculate that an autocrine/paracrine effect of IL-6 was 
responsible for the Fas-mediated activation of the MAP kinase pathway and induction 
of lipolysis. Yet the time course of IL-6 mRNA expression and IL-6 secretion did not 
match each other (Fig. 18B and C). Sant7 reduced the phosphorylation of ERK1/2 
significantly but to a very varying degree in the different experiments (Fig. 19). This 
could be due to a lack of specificity, because Sant7 is a modification of the human IL-
6 molecule. Surprisingly, Sant7 had no effect Fas-induced pSTAT3 (Fig. 19). The 
pan-JAK inhibitor P6 on the contrary only reduced Fas-mediated pSTAT3 and had no 
consistent effect on pERK1/2 (Fig. 20B). We used an antibody that is specific for 
phosphorylated STAT3 on serine 727, a site that is thought to be phosphorylated by 
the MAP kinase or the mTOR pathway (Cell Signalling product information). 
However, the latter findings suggest that Fas-mediated ERK1/2 and STAT3 
phosphorylation are independent events. The JAK2 (and JAK3) inhibitor AG 490 and 
the JAK3 inhibitor WHI-P131 did not decrease the effects of FasL treatment (Fig. 
20A). Taken together with the findings of the P6 experiments this suggests that the 
autocrine/paracrine Fas dependent signal is transduced via JAK1 or TYK2, the forth 
JAK isoform. The use of anti-IL-6 antibodies however further disproved the 
hypothesis that IL-6 is the cause of this signal (Fig. 20C). Therefore, the similar time 
courses of pERK induction and IL-6 mRNA expression (Fig. 5 and 18C) point towards 
an involvement of ERK1/2 in the regulation of IL-6 gene expression. Indeed, the MAP 
kinases were shown to regulated IL-6 transcription in 3T3-L1 cells (76). Therefore, it 
is probable that FasL treatment induces an inflammatory response in adipocytes 
through activation of ERK1/2 that leads to an increase in the secretion of IL-6 and 
other cytokines. On the other hand, the increase in IL-6 and KC secretion was 
significant but, by 1.5 and 2.5 fold respectively, rather low. Such small increase may 
be explained by the fact that apoptosis is executed without inducing an inflammatory 
reaction (74). However, Fas activation was shown to induce ERK1/2 dependent IL-6 
secretion in human glioma cells (77) and injection of an anti-Fas antibody into the 
brain triggers elevated IL-6 plasma levels in mice (78). Furthermore, Fas activation 
induces IL-8 secretion in different cells types. In the HT-29 colon epithelial cell line 
this effect was shown to be independent of apoptosis and dependent on the induction 
of the p38 MAPK and ERK1/2 (79,80). Human rheumatoid arthritis synoviocytes also 
secrete more IL-8 upon Fas activation independent of apoptosis (81). In vascular 
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smooth muscle cells on the other hand Fas-induced apoptosis is not “silent” but 
connected to an inflammatory response (82). These examples illustrate that 
activation of the Fas receptor can induce inflammatory changes in different cellular 
contexts, and this aspect of Fas signalling can be independent of apoptosis and 
mediated by ERK1/2. Decreased Fas-mediated inflammation in adipocytes is most 
probably responsible for the better inflammatory profile of AFasKO mice fed a high fat 
diet. In conclusion, we show that Fas activation induces the production and secretion 
of cytokines in 3T3-L1 adipocytes. However, they do not seem to contribute to FasL-
induced lipolysis.  
 
Our data obtained from experiments with the 3T3-L1 adipocytes suggest that 
activation of the Fas receptor in adipose tissue has significant negative effects on the 
recruitment of new adipocytes as well as on the maintenance of mature adipocytes 
and their metabolism.  
 
As a last thought I would like to ask myself if it would be correct to state here as a 
final conclusion that the Fas receptor induces something extraordinary and 
unexpected in 3T3-L1 adipocytes. We have some indications that Fas activation 
changes lipid and glucose metabolism in adipocytes independent of apoptosis. 
However, it is still tempting to say: “The leaves fell, and we watched them dancing.”      
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Abstract
Aims/hypothesis Adipocytes in obesity are characterised by
increased cell size and insulin resistance compared with
adipocytes isolated from lean patients. However, it is not
clear at present whether hypertrophy actually does drive
adipocyte insulin resistance. Thus, the aim of the present
study was to metabolically characterise small and large
adipocytes isolated from epididymal fat pads of mice fed a
high-fat diet (HFD).
Methods C57BL/6J mice were fed normal chow or HFD
for 8 weeks. Adipocytes from epididymal fat pads were
isolated by collagenase digestion and, in HFD-fed mice,
separated into two fractions according to their size by
filtration through a nylon mesh. Viability was assessed by
lactate dehydrogenase and 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium assays. Basal and insulin-stimulated
d-[U-14C]glucose incorporation and lipolysis were mea-
sured. Protein levels and mRNA expression were determined
by western blot and real-time RT-PCR, respectively.
Results Insulin-stimulated D-[U-14C]glucose incorporation
into adipocytes isolated from HFD-fed mice was reduced
by 50% compared with adipocytes from chow-fed mice.
However, it was similar between small (average diameter
60.9±3.1 μm) and large (average diameter 83.0±6.6 μm)
adipocytes. Similarly, insulin-stimulated phosphorylation of
protein kinase B and AS160 were reduced to the same
extent in small and large adipocytes isolated from HFD-
mice. In addition, insulin failed to inhibit lipolysis in both
adipocyte fractions, whereas it decreased lipolysis by 30%
in adipocytes of chow-fed mice. In contrast, large and small
adipocytes differed in basal lipolysis rate, which was
twofold higher in the larger cells. The latter finding was
associated with higher mRNA expression levels of Atgl
(also known as Pnpla2) and Hsl (also known as Lipe) in
larger adipocytes. Viability was not different between small
and large adipocytes.
Conclusions/interpretation Rate of basal lipolysis but not in-
sulin responsiveness is different between small and large adi-
pocytes isolated from epididymal fat pads of HFD-fed mice.
Keywords Adipocyte size . Insulin resistance .
Insulin sensitivity
Abbreviations
Akt protein kinase B
ATGL adipose triacylglycerol lipase
HFD high-fat diet
HSL hormone-sensitive lipase
ipGTT intraperitoneal glucose tolerance test
LDH lactate dehydrogenase
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
Introduction
Adipocyte hypertrophy has been proposed to induce
adipose tissue dysfunction in obesity, while cell death of
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hypertrophic adipocytes is thought to be a driving force for
macrophage infiltration into adipose tissue [1] and large
adipocytes may secrete higher levels of pro-inflammatory
cytokines [2]. At a more metabolic level, hypertrophic
adipocytes may exhibit a reduced capacity to store and
retain NEFA, leading to elevated levels of circulating NEFA
[3]. In contrast, hyperplastic adipocytes may favour the
deposition of NEFA and thus protect other tissues such as
liver and skeletal muscle from lipotoxicity by sequestering
NEFA away from them [3]. In this regard, treatment with
thiazolidinediones has been shown to increase cellularity in
adipose tissue by promoting pre-adipocyte differentiation
and inducing apoptosis of large adipocytes, resulting in
smaller and more insulin-sensitive adipocytes [4]. Yet, most
studies comparing large and small adipocytes isolated them
from different participants/animals (small adipocytes from
lean, large adipocytes from obese) [5, 6]. Thus, differences
between large and small adipocytes could have resulted
from other factors that differ between lean and obese
sources [5, 6] and not from genuine biological differences
between large and small fat cells within the same biological
context.
Thus, the aim of the present study was to metabolically
characterise large versus small adipocytes isolated from the
same depot of mice fed a high-fat diet (HFD) for 8 weeks.
Such feeding is associated with whole-body insulin
resistance, but with minimal adipocyte cell death and
macrophage infiltration [1]. We hypothesised that insulin
responsiveness in large adipocytes is reduced compared
with small adipocytes isolated from the same fat pad.
Methods
Animals We used 6- to 8-week-old male C57BL6JOlaHsd
mice, which had free access to standard rodent diet or HFD
(D12331; Research Diets, New Brunswick, NJ, USA) for
8 weeks. HFD consisted of 56% of energy derived from fat,
28% from carbohydrate and 16% from protein. In total, 30
mice were used for this study. All protocols conformed to
the Swiss animal protection laws and were approved by the
Cantonal Veterinary Office in Zurich, Switzerland.
Intraperitoneal glucose tolerance test For the intraperito-
neal glucose tolerance test (ipGTT), mice were injected
intraperitoneally with 2 mg/g body weight glucose after
overnight fasting. Blood glucose concentration was mea-
sured with a glucometer (Accu-Check Aviva; Roche
Diagnostics, Rotkreuz, Switzerland) with blood from tail-
tip bleedings [7].
Cell separation and viability assessment Adipocytes isolat-
ed from HFD-fed mice were separated into two fractions
according to their size by filtration through a 60 μm nylon
mesh (Millipore, Zug, Switzerland). Cells caught on the mesh
(large adipocytes) were gently washed away into a separate
vial. After separation, adipocyte viability was assessed with a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide assay (MTT) (Sigma, Buchs, Switzerland) as follows.
Small and large cells were incubated with 0.5 mg/ml MTT
for 1 h and salt was extracted from them with DMSO. The
amount of yellow MTT reduced to purple formazan was
measured spectrophotometrically (550–655 nm) with an
ELISA reader. A lactate dehydrogenase (LDH) release assay
using a nonradioactive cytotoxicity assay (CytoTox 96;
Promega, Dübendorf, Switzerland) was also performed.
LDH released into supernatant fraction was measured and
normalised to cell number in incubation medium.
Glucose incorporation into isolated white adipocytes Adi-
pocyte isolation and glucose incorporation were performed
as described previously [8] with the following adaptations.
Adipocytes (4-8% suspension [9]) were incubated for
60 min with D-[U-14C]glucose. In this setting, most of the
labelled glucose is incorporated into lipids and is therefore
a readout for lipid synthesis [10]. Where indicated, cells
were thereafter separated into two fractions according to
their size by filtration through a 60 μm nylon net filter.
Glucose incorporation was stopped by separating cells from
the medium by centrifugation (about 2000 g) through
phthalic acid dinonyl ester. Cells were then subjected to
liquid scintillation counting. Cell number was determined
with a Neubauer haematocytometer (Brand, Wertheim,
Germany) under the light microscope.
Cell size determination Aliquots of all adipocyte fractions
of each experiment were used to determine mean cell
diameters. Photographs of isolated adipocytes in the
haematocytometer were taken and images were analysed
using ImageJ software for quantification (National Insti-
tutes of Health, Bethesda, MD, USA). At least 100
adipocytes per fraction of four independent experiments
were analysed.
Lipolysis assays To assess lipolysis, cells were separated as
mentioned above and incubated in the absence or presence
of 100 nmol/l insulin or 1 μmol/l isoproterenol (Sigma) for
1 h. NEFA levels were measured using a method (ACS-
ACOD-MEHA) from Wako Chemicals (Neuss, Germany).
Glycerol content of the incubation medium was determined
using a colorimetric assay, as described [11].
RNA extraction and quantitative RT-PCR Total RNA was
extracted using a kit (RNeasy Lipid Tissue Mini Kit;
Qiagen, Basel, Switzerland). RNA (0.5 μg) was reverse-
transcribed with Superscript III Reverse Transcriptase
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(Invitrogen, Basel, Switzerland) using random hexamer
primer. Taqman was used for real-time PCR amplification.
The following PCR primers (Applied Biosystems, Rork-
reuz, Switzerland) were used: Hsl (also known as Lipe)
Mm00495359_m1, Atgl (also known as Pnpla2)
Mm00503040_m1. Relative gene expression was obtained
after normalisation to 36B4 (also known as Rplp0) RNA
(Applied Biosystems), using the formula 2−ΔΔcp.
Western blot Isolated and separated adipocytes were homo-
genised in a buffer containing 150 mmol/l NaCl, 50 mmol/
l Tris–HCl (pH 7.5), 1 mmol/l EGTA, 1% (vol./vol.) NP-40,
0.25% (vol./vol.) sodium deoxycholate, 1 mmol/l sodium
vanadate, 1 mmol/l NaF, 10 mmol/l sodium β-glycerophos-
phate, 100 nmol/l okadaic acid, 0.2 mmol/l phenylmethyl-
sulphonyl fluoride (PMSF) and a 1:1000 dilution of protease
inhibitor cocktail (Sigma). Protein concentration was deter-
mined using the bicinchoninic acid (BCA) assay (Pierce,
Rockford, IL, USA) and equivalent amounts of protein
(40 μg) were resolved by LDS-PAGE (4–12% gel;
NuPAGE; Invitrogen). Proteins were electro-transferred on
to nitrocellulose membranes (0.2 μm; BioRad, Reinach,
Switzerland) and immunoblotted for phosphoS473-protein
kinase B (Akt), phosphoT308-Akt, phosphoAS160 (Cell
Signalling, Beverly, MA, USA), anti-GLUT4 (gift from A.
Klip, The Hospital for Sick Children, Toronto, ON, Canada)
or anti-actin (Millipore, Zug, Switzerland). Membranes
were exposed in an Image Reader and analysed with an
Image Analyzer (FujiFilm, Dielsdorf, Switzerland).
Data analysis Statistical analyses were performed using
either Student’s t test or ANOVA test (Tukey’s multiple
comparisons test).
Results
Separation of adipocytes isolated from HFD-fed mice HFD
for 8 weeks significantly impaired glucose tolerance in
male C57BL6JOlaHsd mice compared with chow-fed
animals as assessed by an ipGTT (Fig. 1a). Adipocytes
isolated from HFD-fed mice were separated into two
Fig. 1 Reduced insulin responsiveness in small and hypertrophic
adipocytes isolated from HFD-fed mice. a Intraperitoneal glucose
tolerance test was performed in chow-fed (grey symbols) and HFD-
fed (black symbols) mice. Glucose (2 g/kg body weight) was injected
intraperitoneally and blood glucose levels measured at indicated time
points. Results are means±SEM of seven (chow-fed) to 24 (HFD-fed)
animals per group. *p<0.05, **p<0.01 (Student’s t test). b Represen-
tative photographs of adipocytes isolated from epididymal fat pads of
chow-fed or HFD-fed mice (scale bar, 250 µm), with graph (c)
showing mean adipocyte diameter of each fraction. Results represent
the mean±SEM of three to four independent experiments. *p<0.05,
**p<0.01 (ANOVA). d Adipocyte viability was assessed by an LDH
and (e) an MTT assay. Results represent the mean±SEM of four
independent experiments. f D-[14C]Glucose incorporation into isolated
adipocytes of chow-fed (grey bars), HFD-fed small (white bars) and
HFD-fed large (black bars) adipocyte fractions. Results represent the
mean±SEM of three to five independent experiments. *p<0.05, **p<
0.01 (ANOVA) compared with insulin-stimulated glucose incorpora-
tion into adipocytes of chow-fed mice. g Total cell lysates were
prepared from isolated adipocytes treated for 10 min with 100 nmol/
l human insulin (Ins). Lysates (40 μg) were resolved by LDS-PAGE
and immunoblotted with anti-phospho (p)S473-Akt, anti-pAS160 or
anti-actin antibody. Representative immunoblots are shown. Mem-
branes were exposed in an Image Reader and quantified (h) with
Image Analyzer. Results represent the mean±SEM of three indepen-
dent experiments. **p<0.01 (ANOVA) compared with chow-fed mice
b
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fractions by filtration through a 60 μm nylon mesh. For
each experiment, epididymal fat pads of two mice were
pooled. Small adipocytes (mean diameter 60.9±3.1 μm)
were significantly smaller than large fat cells (mean
diameter 83.0±6.6 μm; p<0.05) (Fig. 1b, c). For compar-
ison, mean diameter of adipocytes isolated from chow-fed
animals was 50.7±3.3 μm, significantly (p<0.01) smaller
only than the large adipocytes from high-fat fed mice
(Fig. 1b, c). To rule out the possibility of higher occurrence
of cell rupture/cell damage in one cell fraction compared
with the other after filtration through the nylon mesh, cell
viability was assessed by an MTT and LDH assay. As
depicted in Fig. 1d and e, viability of the two adipocyte cell
fractions was comparable.
No difference in insulin-stimulated glucose incorporation
between small and large adipocytes isolated from HFD-fed
mice In order to assess insulin responsiveness, D-[U-14C]
glucose incorporation into adipocytes was determined next.
The fold increase in insulin-stimulated glucose incorpora-
tion into both adipocyte fractions prepared from HFD-fed
mice was greatly reduced compared with adipocytes isolated
from chow-fed animals (Fig. 1f), but surprisingly there was no
difference in glucose incorporation between large and small
adipocytes in HFD-fed mice in response to insulin (Fig. 1f).
This observation held true when the fold-increase in insulin-
stimulated glucose incorporation was calculated per cell
surface or cell volume (data not shown). Accordingly, the
insulin-stimulated increase in phosphorylation of Akt on S473
and on T308 residues as well as of AS160 was similar in both
fractions, but clearly reduced compared with adipocytes
isolated from chow-fed mice (Fig. 1g, h). Similarly, protein
levels of GLUT4 were not different between small and large
adipocytes, but was decreased by approximately 35% com-
pared with adipocytes from chow-fed mice (data not shown).
Increased NEFA release from large epididymal adipocytes
isolated from HFD-fed mice In order to evaluate lipolysis,
concentrations of NEFA and glycerol were determined in
the incubation medium. Basal NEFA release per cell was
significantly higher in large than in small adipocytes
(Fig. 2a), a difference that was not significant when
controlled for surface area. This finding suggests that the
elevated lipolytic activity of the large adipocytes is a direct
effect of cell hypertrophy. Similar results for basal lipolysis
were obtained when release of glycerol was measured
(Fig. 2b). Isoproterenol-stimulated lipolysis was significantly
increased compared with basal NEFA release, but not
different between small and large adipocytes from HFD-fed
mice (Fig. 2a). Remarkably, the ability of insulin to inhibit
lipolysis was fully blunted in large and small adipocytes
compared with adipocytes from chow-fed mice (in which
lipolysis was inhibited by ∼30%) (Fig. 2c), a finding that is
consistent with the similar degree of insulin resistance
observed in signalling and glucose incorporation (Fig. 1d).
Adipose triacylglycerol lipase (ATGL) and hormone-
sensitive lipase (HSL) are key players in adipocyte lipolysis.
It has been suggested that ATGL and HSL may act in
coordination such that ATGL is the primary lipase responsible
for hydrolysing the first fatty acid from triacylglycerol and that
HSL is the primary diacylglycerol lipase [12]. Alternatively, it
has been proposed that HSL is the primary triacylglycerol
lipase responsible for catecholamine-stimulated lipolysis from
adipocytes and ATGL is the primary triacylglycerol lipase for
basal lipolysis [13]. Given the differences in basal lipolysis
rate between large and small adipocytes, mRNA expression
levels of these two lipases were determined. There was a slight
but significant increase in Atgl mRNA levels in large
adipocytes (Fig. 2d). Similarly, Hsl expression tended to be
higher in large adipocytes; however, this increase did not
reach statistical significance.
Discussion
Adipocytes from obese persons or animals compared with
those from lean persons or animals are characterised by
Fig. 2 Increased basal lipolysis in large adipocytes. a Basal and
isoproterenol-stimulated NEFA release from HFD small (white bars)
and HFD large (black bars) adipocytes. Results are means±SEM of
five (isoproterenol) to seven (basal) independent experiments. *p<
0.05 (Student’s t test). b Basal glycerol release from HFD small and
HFD large adipocytes. Results are means±SEM of three independent
experiments. *p<0.05 (Student’s t test). c Per cent inhibition of NEFA
release by insulin in chow-fed, HFD-fed small and HFD-fed large
adipocytes. Results represent the mean±SEM of three to five
independent experiments. d Quantitative RT-PCR detection of Atgl
and Hsl mRNA expression. The level of mRNA expression was
normalised to 36B4 RNA. Results represent the mean±SEM of three
independent experiments and are expressed relative to expression in
the HFD-small fraction. *p<0.05 (Student’s t test)
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increased cell size and decreased insulin-stimulated glucose
uptake [14, 15]. It has therefore been speculated that larger
adipocytes are more insulin resistant. Although this conclu-
sion is plausible, it is difficult to analyse the sole contribution
of cell size to insulin resistance independently of other
factors since cells are isolated from different individuals. It is
possible that these factors, along with or independently of
cell size, causatively contribute to the insulin resistance
observed in adipocytes derived from the obese.
To address this point, we have characterised larger
versus smaller adipocytes from the same fat depot of mice
fed HFD for 8 weeks. The time span of 8 weeks of HFD
was chosen to examine an early phase of obesity-induced
changes in adipose tissue. Macrophage infiltration of
adipose tissue and occurrence of adipocyte death may have
just started at this time point [1]. Yet, 8 weeks of fat-
enriched diet was already sufficient to induce whole-body
insulin resistance as demonstrated by a significantly
impaired ipGTT (Fig. 1a), by a reduction in insulin-
stimulated glucose incorporation (Fig. 1f) and by a blunted
capacity of insulin to inhibit lipolysis (Fig. 2c). Neverthe-
less, when comparing large to small adipocytes isolated
from HFD-fed mice, we did not detect any differences in
insulin responsiveness (Figs 1f and 2c). This observation
was true both for insulin-mediated stimulation of glucose
incorporation, as well as for the inhibition of lipolysis. It is still
possible that the severity of insulin resistance differs between
the extremes of adipocyte size. Yet for the cell size range of
most adipocytes composing the adipose tissue of HFD mice,
the data would suggest that the degree of cellular hypertrophy
is not a direct determinant of severity of adipocyte insulin
resistance. More probably, insulin resistance in adipocytes of
HFD-fed mice could be a secondary phenomenon to alter-
ations in the intra-fat depot environment, such as increased
release of pro-inflammatory cytokines and/or NEFA. These
would seem to similarly affect insulin sensitivity in larger
versus smaller adipocytes within the same fat depot.
One of the main findings in the present study is the
significant increase in basal lipolysis in large compared
with small adipocytes (Fig. 2a, b). This finding is in
accordance with a previous study showing a correlation of
adipocyte size with basal rates of lipolysis [16]. The latter
finding would imply increased circulating NEFA levels in
patients with adipocyte hypertrophy. Indeed, enlarged
adipocytes were found more frequently in patients with
obesity-related metabolic disorders [17], suggesting that
increased basal lipolysis of large adipocytes may directly
contribute to obesity-induced metabolic alterations, poten-
tially via deposition of lipids in liver and skeletal muscle
(lipotoxicity). It would be intriguing to assess whether, by
increasing local NEFA concentrations in adipose tissue,
large adipocytes contribute to the insulin resistance that
similarly develops in large versus small adipocytes.
Intriguingly, whereas NEFA-induced insulin resistance is a
well established phenomenon in skeletal muscle and liver,
results in adipocytes are somewhat controversial [18, 19],
leaving this putative mechanism unsettled.
In conclusion, adipocyte hypertrophy associated with
diet-induced obesity does not seem to be a direct
determinant of the severity of adipocyte insulin resistance.
Instead, larger adipocytes have a higher basal lipolysis rate
than smaller adipocytes. Hence, of the various alterations to
adipose tissue in obesity, adipocyte hypertrophy may
predominantly, albeit indirectly, contribute to whole-body
insulin resistance, e.g. by affecting the release of secreted
products like adipokines and NEFAs.
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Adipose	tissue	inflammation	is	linked	to	the	pathogenesis	of	insulin	resistance.	In	addition	to	exerting	death-
promoting	effects,	the	death	receptor	Fas	(also	known	as	CD95)	can	activate	inflammatory	pathways	in	several	
cell	lines	and	tissues,	although	little	is	known	about	the	metabolic	consequence	of	Fas	activation	in	adipose	
tissue.	We	therefore	sought	to	investigate	the	contribution	of	Fas	in	adipocytes	to	obesity-associated	metabolic	
dysregulation.	Fas	expression	was	markedly	increased	in	the	adipocytes	of	common	genetic	and	diet-induced	
mouse	models	of	obesity	and	insulin	resistance,	as	well	as	in	the	adipose	tissue	of	obese	and	type	2	diabetic	
patients.	Mice	with	Fas	deficiency	either	in	all	cells	or	specifically	in	adipocytes	(the	latter	are	referred	to	herein	
as	AFasKO	mice)	were	protected	from	deterioration	of	glucose	homeostasis	induced	by	high-fat	diet	(HFD).	
Adipocytes	in	AFasKO	mice	were	more	insulin	sensitive	than	those	in	wild-type	mice,	and	mRNA	levels	of	pro-
inflammatory	factors	were	reduced	in	white	adipose	tissue.	Moreover,	AFasKO	mice	were	protected	against	
hepatic	steatosis	and	were	more	insulin	sensitive,	both	at	the	whole-body	level	and	in	the	liver.	Thus,	Fas	in	adi-
pocytes	contributes	to	adipose	tissue	inflammation,	hepatic	steatosis,	and	insulin	resistance	induced	by	obesity	
and	may	constitute	a	potential	therapeutic	target	for	the	treatment	of	insulin	resistance	and	type	2	diabetes.
Introduction
White adipose tissue (WAT) has been recognized as an important 
endocrine organ secreting different hormone-like factors (adipo-
kines), FFAs, and cytokines, thereby regulating metabolism locally 
and systemically (1). In obesity, excess adipose tissue accumulation 
is accompanied by local inflammation, characterized by infiltra-
tion of inflammatory cells (2) and by elevated production of proin-
flammatory cytokines, jointly activating inflammatory pathways 
in adipocytes. It is proposed that the consequent alteration in the 
composition of secreted products from adipocytes contributes 
to both local and systemic insulin resistance (3–5). Particularly, 
liver insulin sensitivity can be impaired by obesity-induced altera-
tions in adipokine secretion and by elevation in fat tissue–derived 
cytokines and fatty acids (6–9).
Fas (CD95), a member of the TNF receptor family, plays an 
important role in the regulation of programmed cell death (apop-
tosis). FasL binding to Fas assembles the death-inducing signaling 
complex (DISC). In turn, DISC formation leads to the activation 
of caspase-8 and caspase-3 and finally to apoptosis. However, like 
TNF-α, Fas activation can also induce non-apoptotic signaling 
pathways (10–12). For example, in different cell lines and tissues, 
Fas activation was shown to induce secretion of proinflamma-
tory cytokines such as IL-1α, IL-1β, IL-6, IL-8 (KC), and MCP-1 
(13–17), rendering it a potential key component of the inflamma-
tory response. Although Fas was shown to be expressed in preadi-
pocytes and adipocytes (18), little is known about non-apoptotic 
consequences of Fas activation in adipocytes and, particularly, its 
role in mediating the dysregulated metabolism that accompanies 
obesity, potentially via adipose tissue inflammation.
In the present study, we hypothesized that Fas mediates inflam-
matory signals in obesity, particularly in adipocytes, thereby con-
tributing to adipose tissue inflammation and to metabolic dysreg-
ulation. We demonstrate that Fas expression is elevated in adipose 
tissue in both genetic and nutritional models of obesity in mice, as 
well as in patients with obesity and type 2 diabetes. Moreover, total 
body Fas-deficient (Fas-def) and adipocyte-specific Fas-KO (AFas-
KO) mice were partly protected from HFD-induced adipocyte and 
whole-body insulin resistance. In particular, AFasKO mice showed 
reduced adipose tissue inflammation and were protected from 
liver steatosis and hepatic insulin resistance, with only minimal 
effects on fat tissue mass and adipocyte hypertrophy. Our find-
ings point toward an important role of adipocyte Fas expression 
in the development of obesity-associated fat tissue inflammation 
and insulin resistance.
Results
Fas expression is increased in adipocytes isolated from insulin-resistant mice 
and in adipose tissue of obese and diabetic patients. Fas was shown to acti-
vate inflammatory pathways in several tissues and cell lines. Since 
Fas is expressed in preadipocytes and adipocytes (18), and since 
adipose tissue inflammation may be causatively linked to insulin 
resistance, we hypothesized that Fas expression might modulate 
obesity-related fat and whole-body insulin responsiveness. First, 
Fas expression was determined in isolated adipocytes from insulin-
resistant mice. Adipocytes were isolated from perigonadal fat pads 
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of 3-month-old ob/ob and db/db mice and their WT controls. Fas 
protein expression was determined and normalized to actin expres-
sion (19) (Figure 1A). Fas protein levels were significantly increased 
in ob/ob as well as db/db mice compared with their WT controls. 
Similarly, Fas protein expression was increased in adipocytes iso-
lated from perigonadal fat pads of high-fat diet–fed (HFD-fed) 
C57BL/6J mice compared with regular chow–fed controls (Figure 
1B). In addition to Fas, we also found Fasl, Tnfa, and Il1b mRNA 
levels elevated in adipose tissue of ob/ob mice (Figure 1C).
In order to determine the potential relevance of increased Fas 
expression in adipose tissue of patients with insulin resistance, we 
determined Fas protein levels in adipose tissue of lean, obese, and 
obese type 2 diabetic patients. None of the examined patients was 
treated with any medications that might affect inflammatory path-
ways in adipose tissue or modulate insulin sensitivity (further basic 
clinical characteristics of the patients are provided in Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI38388DS1). Fas expression was increased in fat tis-
sue of obese (body mass index, >30 kg/m2) compared with lean per-
sons. Interestingly, Fas was further elevated in obese patient with 
type 2 diabetes (Figure 1D). Collectively, these data demonstrate 
that Fas expression is upregulated in isolated adipocytes of common 
genetic and nutritional mouse models of obesity and insulin resis-
tance and in adipose tissue of obese and obese diabetic humans.
Fas-def mice are protected against HFD-induced insulin resistance. To 
start assessing a putative metabolic role for increased adipocyte 
Fas expression under insulin-resistant conditions, we analyzed glu-
cose tolerance in total body Fas-def mice (20). Fas-def or WT mice 
were fed regular chow or HFD for 6 weeks. Total body weight gain 
on HFD was similar in Fas-def and WT mice (Figure 2A). However, 
perigonadal fat pad weight was significantly lower in HFD-fed Fas-
def mice compared with WT mice (Figure 2B), and adipocyte size 
distribution was shifted to the left, reflecting smaller mean adipo-
cyte size in Fas-def mice (Figure 2C). Adipocyte number was simi-
lar in HFD-fed WT and Fas-def mice (data not shown), suggesting 
that fat pads in Fas-def mice are smaller due to the smaller size of 
adipocytes. Six weeks of HFD was sufficient to significantly impair 
glucose tolerance in WT mice (Figure 2D), though the degree of 
impairment was less than reported following a longer duration 
of HFD feeding (20 weeks), reflecting early metabolic adaptation 
to HFD feeding. Remarkably, Fas-def mice were protected against 
HFD-induced glucose intolerance (Figure 2D). Further, consis-
tent with Fas involvement in the induction of insulin resistance, 
fasting insulin levels increased significantly in WT mice fed HFD 
compared with chow-fed controls, whereas in Fas-def mice, there 
was no diet-induced change in fasting insulin levels (Figure 2E). 
Concurrently, isolated adipocytes from HFD-fed WT mice exhib-
ited a marked reduction in insulin-stimulated glucose incorpora-
Figure 1
Fas expression is increased in adipocytes isolated from insulin-resistant mice and in adipose tissue of obese and diabetic patients. (A) Total 
cell lysates were prepared from isolated perigonadal adipocytes harvested from db/db, ob/ob, and WT control mice. Lysates were resolved by 
LDS-PAGE and immunoblotted with anti-Fas or anti-actin antibody. Results are mean ± SEM of 3 mice per group and normalized to actin expres-
sion. *P < 0.05 (Student’s t test). (B) Total cell lysates were prepared from isolated adipocytes of perigonadal fat pads of chow-fed and HFD-fed 
(8 weeks of HFD) mice. Lysates were resolved by LDS-PAGE and immunoblotted with anti-Fas or anti-actin antibody. Results are mean ± SEM 
of 3 mice per group and normalized to actin expression. *P < 0.05 (1-sample t test). (C) Total RNA was extracted from perigonadal fat pads, and 
quantitative RT-PCR was performed. The level of mRNA expression was normalized to 18S RNA. Results represent mean ± SEM of 3 animals 
per group. *P < 0.05, **P < 0.01 (Student’s t test). (D) Tissue lysates from subcutaneous fat biopsies of lean, obese, and diabetic patients were 
prepared and immunoblotted with anti-Fas or anti-actin antibody. Results are mean ± SEM of 5–10 patients per group and normalized to actin 
expression. *P < 0.05 (ANOVA).
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Figure 2
Fas-def mice are protected from 
HFD-induced changes in adipose 
tissue and glucose homeostasis. 
(A) Weight gain was analyzed in 
HFD-fed WT and Fas-def mice. 
Results are mean ± SEM of 10 
animals per group. (B) Perigonad-
al fat pads were harvested and 
weighed. Results are expressed 
relative to total body weight and 
represent mean ± SEM of 10–15 
mice group. *P < 0.05 (Student’s 
t test). (C) Left: Relative size dis-
tribution of adipocyte diameter 
after 6 weeks of HFD. Results 
represent mean ± SEM of 6 mice 
per group. Right: Mean adipocyte 
diameter of chow- or HFD-fed 
Fas-def and WT mice. Results 
represent mean ± SEM of 6 mice 
per group. *P < 0.05 (Student’s 
t test). (D) Intraperitoneal glucose 
tolerance tests in WT (left) and 
Fas-def (right) mice. Results are 
mean ± SEM of 12–18 animals 
per group. *P < 0.05, **P < 0.01 
(Student’s t test). (E) Fasting 
insulin levels were determined in 
WT (left) and Fas-def (right) mice 
after 8 hours of food withdrawal. 
Results are mean ± SEM of 4–5 
animals per group. *P < 0.05 
(Student’s t test). (F) 14C-d-glu-
cose incorporation into isolated 
adipocytes from chow- and HFD-
fed mice was determined in the 
absence or presence of insulin. 
Left: Fold glucose incorporation 
in WT mice. Right: Fold glucose 
incorporation in Fas-def mice. 
Results represent mean ± SEM 
of 6 experiments. **P < 0.01 (Stu-
dent’s t test).
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tion (largely reflecting lipogenic glucose flux; ref. 21) compared 
with chow-fed mice, whereas adipocytes from Fas-def mice were 
almost entirely protected against diet-induced adipocyte insulin 
resistance (Figure 2F). Similarly, insulin significantly reduced FFA 
release in adipocytes isolated from Fas-def mice, whereas it had 
no effect in WT adipocytes (Supplemental Figure 1). Thus, total 
body deficiency of Fas resulted in protection against adipose tissue 
expansion and adipocyte hypertrophy as well as whole-body and 
adipocyte insulin resistance induced by 6 weeks of HFD feeding.
Given the seemingly complex effect of Fas on adipose tissue devel-
opment and on fat cell metabolism in response to HFD, we wanted 
to verify that Fas activation, even as an isolated factor, modulates 
insulin sensitivity in adipocytes. 3T3-L1 adipocytes were stimulated 
with 2 ng/ml membrane-bound FasL for 12 hours. Such treat-
ment had no negative effect on cell viability and did not increase 
apoptosis rate as assessed by MTT and TUNEL assays, respectively 
(Supplemental Figure 2 and data not shown). Yet Fas activation sig-
nificantly reduced insulin-stimulated glucose uptake (Figure 3A) 
and stimulated lipolysis (Figure 3B). Lower FasL concentrations 
(0.02, 0.5, and 1.0 ng/ml) had no effect on insulin-stimulated glu-
cose uptake (Supplemental Figure 3). These findings support the 
proposition that adipocyte Fas may regulate fat cell metabolism by 
mechanisms unrelated to Fas-induced cell death, potentially con-
tributing to obesity-related insulin resistance.
AFasKO mice are protected against HFD-induced adipocyte insulin resis-
tance and total body insulin resistance. To better investigate the specific 
role of Fas expression in adipocytes in the development of insulin 
resistance in response to HFD feeding, we generated an adipocyte-
specific Fas-KO mouse (AFasKO) using the Cre-lox system (Fasfl/fl; 
Fabp4-Cre+/–). As a control, floxed Fas mice that do not express Cre 
recombinase (Cre) were used (Fasfl/fl;Fabp4-Cre–/–), referred to below as 
WT. As expected, Fas expression was greatly diminished in isolated 
white adipocytes of AFasKO mice (Figure 4A); decreased in white 
and brown adipose tissue, which also includes non-adipocyte cell 
types (Figure 4B); but was not decreased in other tissues (Figure 4C) 
(an unexplained consistent increase in Fas expression was observed 
in lysates from lung tissue).
It was previously  claimed  that  fatty acid binding protein 4 
(Fabp4)/aP2 expression was induced in activated macrophages 
(22). Given the fact that Cre expression in our mice is under the 
regulation of the Fabp4 pro-
moter, Fas expression might 
have been decreased  in acti-
vated macrophages  in  addi-
tion  to  adipocytes,  thereby 
influencing  adipose  tissue 
biology.  However,  Cre  was 
expressed  in  adipocytes  of 
AFasKO mice, whereas it was 
undetectable in macrophages 
(Figure 4D), consistent with 
previous  studies  using  the 
same Fabp4-Cre strain (19, 23). 
Moreover,  in  both  resident 
(naive) macrophages isolated 
from the spleen and  in acti-
vated peritoneal macrophages 
harvested after thioglycollate 
injection, Fas protein expres-
sion  was  not  decreased  in 
AFasKO mice (Figure 4E). Although it still remains possible that a 
small subpopulation of activated macrophages within adipose tis-
sue express decreased levels of Fas in the AFasKO mice, this novel 
mouse model exhibits greatly diminished Fas expression in adi-
pocytes but not in other tissues and cell types, including resident 
and activated peritoneal macrophages. Moreover, since previous 
studies using the same Fabp4-Cre mouse line found no effect of the 
Cre allele in the first 6 months of life (23), AFasKO mice seemed 
to be a useful model to study the in vivo role of Fas expression 
specifically in adipocytes.
To investigate the functional significance of adipocyte-specific 
Fas deletion, AFasKO mice were fed normal chow or HFD for up 
to 6 weeks. Total body weight gain was similar in AFasKO and 
Cre-negative littermates fed normal chow (data not shown) and 
HFD (Figure 4F). After 6 weeks of HFD, inguinal, perigonadal, 
and retroperitoneal fat pad weights in the AFasKO mice were com-
parable to those in WT mice, whereas mesenteric fat pad weight 
was slightly, but significantly, lower in AFasKO mice (Figure 4G). 
Importantly, and in contrast to total body Fas-def mice, adipocyte 
size was similar in the 2 groups (Figure 4H).
Blood glucose levels were significantly higher in WT mice after 
a 7-hour fasting period, whereas insulin, FFA, triglyceride (TG), 
and glycerol levels did not differ between WT and AFasKO mice 
(Table 1). Moreover, adipocytes isolated from AFasKO mice exhib-
ited improved insulin-stimulated glucose incorporation, compared 
with adipocytes from WT mice after 6 weeks of HFD (Figure 5A). 
Further, consistent with improved adipocyte insulin sensitivity 
in the absence of Fas expression in adipocytes, insulin still had a 
significant antilipolytic effect in isolated adipocytes of HFD-fed 
AFasKO mice, compared with adipocytes of WT mice (49% ± 19% 
vs. 26% ± 7%), whereas basal FFA release was not different in the 2 
groups. Thus, specific ablation of Fas expression in adipocytes was 
associated with protection against the metabolic effects of HFD 
feeding in adipocytes, without affecting adipocyte size.
To examine whether improved insulin responsiveness of adipo-
cytes conferred by adipocyte-specific Fas deletion had systemic 
consequences, we assessed glucose metabolism. There were no dif-
ferences in glucose and insulin tolerance test results between chow-
fed 3-month-old AFasKO and WT littermates (data not shown). In 
contrast, after 6 weeks of HFD, AFasKO mice exhibited mildly but 
Figure 3
Fas activation in 3T3-L1 adipocytes decreases insulin sensitivity and stimulates lipolysis. Mature 3T3-L1 adipo-
cytes were incubated with 2 ng/ml FasL for 12 hours. (A) 3H-2dG glucose uptake was determined after treatment 
with or without insulin at different concentrations. Shown are absolute values of 3H-2dG uptake in untreated or 
FasL-treated 3T3-L1 adipocytes. Results are mean ± SEM of 5–9 independent experiments. *P < 0.05 (ANOVA). 
(B) Glycerol release was determined after medium was removed and cells were incubated with KREBS buffer for 
another hour. Results represent mean ± SEM of 4 independent experiments. **P < 0.01 (1-sample t test).
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significantly improved glucose tolerance compared with Cre-nega-
tive littermates (Figure 5B). Moreover, AFasKO mice were signifi-
cantly more insulin sensitive as assessed by insulin tolerance test 
(Figure 5C). Finally, under hyperinsulinemic-euglycemic clamp, 
glucose infusion rate was significantly increased in AFasKO mice 
compared with WT littermates (see Figure 5D for the steady-state 
glucose infusion rates and Supplemental Figure 4 for the detailed 
time course), confirming improved whole-body insulin sensitivity. 
In vivo lipolysis determined during hyperinsulinemic-euglycemic 
clamp showed no difference in basal FFA levels, but insulin had 
a significant effect in reducing circulating FFA in AFasKO mice, 
while this effect was blunted in WT littermates (Figure 5E). Based 
on the results presented herein, we describe an adipocyte-specific 
Fas-KO mouse model  that  is protected against adipocyte and 
whole-body insulin resistance induced by HFD feeding.
Fas deletion in adipocytes may prevent adipocyte and whole-body insulin 
resistance by interfering with adipose tissue inflammatory circuits induced 
by HFD feeding. Given that Fas may be involved in inflammatory 
processes, we next assessed its potential involvement in adipose 
tissue inflammation. mRNA levels of major inflammatory mark-
ers were assessed in adipose tissue of HFD-fed WT versus AFasKO 
mice. In the KO mice, fat mRNA levels of Il6, Cd11b, Mcp1, and 
resistin were significantly decreased, whereas Il10 and arginase 1 
levels were increased (Figure 6A and Supplemental Table 2). Since 
adipose tissue is proposed to be a major source of circulating levels 
of cytokines such as MCP-1 and IL-6 (24, 25), we measured their 
levels in the circulation. Whereas circulating MCP-1 levels were not 
significantly different between WT and AFasKO mice after 6 weeks 
of HFD, IL-6 levels were approximately 40% lower in the KO mice 
(Figure 6B and Table 1), and KC levels (murine IL-8 equivalent) 
tended to be decreased (Table 1). Circulating levels of the adipo-
kines adiponectin, resistin, and leptin were not affected (Table 1), 
the latter finding being further consistent with a lack of a signifi-
cant effect of adipocyte-specific Fas deletion on whole-body fat 
mass. These results suggest that the proinflammatory profile of 
secreted products from adipose tissue of AFasKO mice in response 
to HFD feeding is diminished compared with WT mice.
To further confirm a role for Fas activation, even as an isolated 
factor, in propagating adipocyte inflammatory response, we used 
3T3-L1 adipocytes. Fas activation by incubation of cells for 12 
hours with FasL increased the release of IL-6 and KC into the medi-
um by 1.5 ± 0.1–fold and 2.8 ± 0.5, respectively (P < 0.05 for both 
Figure 4
Characterization of AFasKO mice. (A) Total cell lysates were prepared from isolated adipocytes of WT (Fasfl/fl;Fabp4-Cre–/–) and AFasKO (Fasfl/fl; 
Fabp4-Cre+/–) mice. Lysates were resolved by LDS-PAGE and immunoblotted with anti-Fas or anti-actin antibody. (B and C) Tissue lysates 
were prepared and resolved by LDS-PAGE and immunoblotted with anti-Fas or anti-actin antibody. (D) Total cell lysates (80 μg) from adipocytes 
and macrophages were prepared, resolved by LDS-PAGE, and immunoblotted with anti-Cre or anti-actin antibody. (E) Total cell lysates from 
resident and activated macrophages were prepared, resolved by LDS-PAGE, and immunoblotted with anti-Fas or anti-actin antibody. (F) Weight 
gain was analyzed in WT and AFasKO mice. Results are mean ± SEM of 14–15 animals per group. (G) Different fat pads were harvested and 
weighed. Results are expressed relative to total body weight and represent mean ± SEM of 14 mice per group. *P < 0.05. peri, perigonadal; retro, 
retroperitoneal; mes, mesenteric. (H) The size of isolated perigonadal adipocytes was analyzed. For each mouse, at least 100 adipocytes were 
analyzed. Images were analyzed using NIH ImageJ software for quantification. Results represent mean ± SEM of 4–5 mice per group.
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cytokines compared with unstimulated cells; Figure 7A). Moreover, 
according to an in vitro macrophage-adipocyte adherence assay, 
macrophages adhered significantly more readily to FasL-treated 
3T3-L1 adipocytes (25% ± 9% increase in macrophages adherent 
to adipocytes, P < 0.05; Figure 7B). These findings are consistent 
with the observation that AFasKO mice on a HFD had decreased 
expression of adipose tissue CD11b (probably reflecting decreased 
infiltrating leukocytes) (Figure 6A and Supplemental Table 2) and 
collectively suggest a role for Fas as an activator of adipocyte-
derived inflammation under HFD.
Fas ablation in adipocytes protects against liver steatosis and insu-
lin resistance induced by HFD. Adipose tissue inflammation has 
been linked to hepatic manifestations of obesity. In particular, 
the degree of adipose tissue macrophage infiltration correlated 
with histopathological changes in the liver (26). Moreover, JNK1 
deficiency specifically in adipocytes was recently shown to cause 
increased hepatic insulin sensitivity (19). Hence, we next addressed 
the possibility that adipocyte Fas deletion protects from hepatic 
insulin resistance and steatosis along with diminished adipose 
tissue inflammation. Histological examinations and biochemi-
cal determination of total hepatic lipid content revealed that 
the livers of AFasKO mice were protected against liver steatosis 
induced by HFD (Figure 8A). Furthermore, AFasKO mice had sig-
nificantly decreased liver ceramide levels, whereas diacylglycerol 
levels were similar in AFasKO and WT mice (Figure 8B and data 
not shown). Moreover, mRNA levels of the fatty acid transporter 
Cd36 were reduced by 27% (P < 0.05) in livers of AFasKO mice, 
whereas mRNA levels of genes involved in gluconeogenesis, β-oxi-
dation, and lipogenesis were similar (Figure 8C). Consistent with 
decreased steatosis in AFasKO livers, protein content of the lipid 
droplet protein adipose differentiation related protein (ADRP) 
and the lipogenic transcription factor PPARγ were decreased in 
AFasKO compared with WT mice (Figure 8D) (27). In addition, 
liver steatosis was associated with activation of the NF-κB signal-
ing pathway (28). Intriguingly, activation of NF-κB was reduced to 
35% in livers of AFasKO mice compared with WT mice, as assessed 
by phosphorylation of the p65 subunit of NF-κB (Figure 8E).
Molecularly, liver resistance to insulin actions was suggested to 
be mediated by increased Ser307 phosphorylation on IRS1 and 
by increased expression of SOCS3 (19). Interestingly, AFasKO 
mice had 50% lower levels of IRS1 phosphorylation on Ser307 
(Figure 9A). In addition, expression of Socs3 mRNA levels (relative 
to 18S) was reduced by 25%. Circulating glucose levels following 
a pyruvate load suggested that AFasKO mice had lower gluconeo-
genic flux compared with WT mice on HFD (Supplemental Fig-
ure 5). Moreover, during a hyperinsulinemic-euglycemic clamp, 
insulin-induced suppression of hepatic glucose production was 
blunted in HFD-fed WT mice but was clearly evident in AFasKO 
mice (Figure 9B).
To further support a role for adipocyte-expressed Fas in the 
development of HFD-induced liver insulin resistance, we per-
formed experiments with conditioned medium. 3T3-L1 adipo-
cytes were treated with or without FasL, and conditioned medium 
was then collected. Hepatocytes incubated with FasL-conditioned 
medium developed insulin resistance, as shown by decreased insu-
lin-stimulated phosphorylation of Akt (Figure 9C).
Collectively, these studies demonstrate that in the absence of Fas 
in adipocytes, mice are protected against hepatic steatosis and liver 
insulin resistance induced by HFD.
Discussion
In the present study, we demonstrate that both total body Fas-
deficient mice and a novel adipocyte-specific Fas-KO model were 
significantly protected against insulin resistance induced by HFD 
feeding, at the adipocyte, liver, and whole-body levels. Our find-
ings suggest that Fas-mediated pathways in adipocytes play a role 
in obesity-associated insulin resistance by modulating adipose tis-
sue inflammatory cascades.
Our finding of reduced fat pad weight and lack of an increase in 
adipocyte size under HFD in Fas-def mice (Figure 2C) hints at a 
role of Fas in modulating adipocyte development and/or differen-
tiation, as Fas is not expressed in preadipocytes and adipocytes of 
Fas-def mice. Thus, the metabolic effect of Fas may be secondary 
to its effect on adipocyte differentiation. In contrast, since Fabp4 
is downstream of PPARγ, Cre is only expressed during late stages 
of adipocyte differentiation in the AFasKO mice, as was previ-
ously shown (23). Consistent with such a notion, adipocyte size of 
AFasKO mice did not differ from WT mice after 6 weeks of HFD 
(Figure 4H). Thus, early adipocyte development was unlikely to 
be affected in AFasKO mice, as opposed to Fas-def mice, and the 
hypertrophic response of adipocytes to HFD remained similar to 
that in control mice. Moreover, we assessed the potential influence 
of Fas stimulation on preadipocyte differentiation by treating 3T3-
L1 (pre)adipocytes with FasL during differentiation. We found that 
markers of differentiation such as C/EBPβ, C/EBPα, and PPARγ 
were reduced (Supplemental Figure 6). Furthermore, it is possible 
that Fas expression in other cells is indirectly involved in adipocyte 
growth/differentiation, as was previously shown for macrophages 
(29), explaining the observation that adipocytes were affected to 
a greater extent in the Fas-def model than in the AFasKO model. 
Similar to the reduction in markers of differentiation in FasL-treat-
ed 3T3-L1 adipocytes (Supplemental Figure 6), PPARγ was signifi-
cantly reduced in WAT of WT compared with AFasKO mice upon 
6 weeks of HFD, whereas C/EBPα showed a trend toward lower 
expression levels in WT mice (Supplemental Figure 7).
Additional support for the involvement of Fas in obesity-relat-
ed adipose tissue inflammation was initially gained by finding 
increased expression of Fas in both common genetic and nutri-
tional mouse obesity models and in obese humans. Interestingly, 
Table 1
Plasma levels of glucose, insulin, FFAs, TG, glycerol, adipokines, 
and cytokines of HFD-fed WT and AFasKO mice
	 WT	 AFasKO
Blood glucose (mmol/l) 10.6 ± 0.3 9.4 ± 0.4A
Insulin (pmol/l) 98.5 ± 17.7 89.1 ± 7.8
FFAs (mmol/l) 1.36 ± 0.06 1.33 ± 0.04
TG (mg/dl) 85.9 ± 4.1 85.9 ± 6.5
Glycerol (mg/dl) 6.72 ± 0.37 6.52 ± 0.38
Adiponectin (μg/ml) 52.9 ± 5.7 56.4 ± 4.4
Resistin (pg/ml) 4,465 ± 516 5,251 ± 730
Leptin (pg/ml) 1,270 ± 305 1,240 ± 209
MCP-1 (pg/ml) 47.5 ± 12.9 35.1 ± 7.8
IL-6 (pg/ml) 7.6 ± 0.9 4.6 ± 1.0A
KC (pg/ml) 481 ± 139 278 ± 54
TNF-α ND ND
Results are mean ± SEM of 5–9 independent experiments. ND, not 
detectable (limit of detection, 3 pg/ml). AP < 0.05 (Student’s t test).
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4 days of HFD feeding was sufficient to upregulate Fas expression 
in adipocytes (Supplemental Figure 8). This finding suggests that 
upregulation of Fas in adipocytes reflects an early adaptation 
step to HFD. To further establish a functional role for adipocyte 
Fas in adipose tissue inflammation in obesity, we established the 
AFasKO mouse, which displays a specific deletion of Fas in adi-
pocytes. Adipose tissue inflammation in obesity is characterized 
by increased infiltration of bone-derived immune cells, particu-
larly proinflammatory macrophages, and elevated expression and 
secretion of proinflammatory cytokines, with decreases in IL-10 
and arginase 1 (30). Intriguingly, HFD-fed AFasKO mice exhibited 
decreased leukocyte infiltration (evidenced by lower expression of 
CD11b), diminished expression of IL-6, and increased expression 
of IL-10 and arginase 1 compared with WT controls (Figure 6A 
and Supplemental Table 2). Moreover, in support of the hypothe-
sis that Fas acts as an isolated factor to promote macrophage infil-
Figure 5
AFasKO mice are protected from HFD-induced deteriorations in glucose metabolism. (A) 14C-d-glucose incorporation into isolated perigonadal 
adipocytes from WT (Fasfl/fl;Fabp4-Cre–/–) and AFasKO (Fasfl/fl;Fabp4-Cre+/–) mice was determined in the absence or presence of insulin. Results 
are expressed relative to basal uptake and represent mean ± SEM of 5 independent experiments performed in triplicate. *P < 0.05 (Student’s 
t test). Intraperitoneal glucose (B) and insulin (C) tolerance tests (ipGTT and ipITT) were performed in WT (filled circles) and AFasKO (open 
circles) mice. Inset graphs in B and C depict the respective analysis of the area under the curve. Results are mean ± SEM of 8–10 animals per 
group. *P < 0.05, **P < 0.01 (Student’s t test). (D) Steady-state glucose infusion rates during hyperinsulinemic-euglycemic clamps. Results are 
mean ± SEM of 3–4 animals per group. **P < 0.01 (Student’s t test). (E) Plasma FFA levels in HFD-fed WT and AFasKO mice before and at the 
end of a euglycemic-hyperinsulinemic clamp are depicted. Results are mean ± SEM of 3 animals per group. *P < 0.05 (Student’s t test).
Figure 6
Reduced inflammatory profile in HFD-fed 
AFasKO mice. (A) Quantitative RT-PCR 
detection of mRNA expression in WAT. The 
level of mRNA expression was normalized 
to 18S RNA. Results are mean ± SEM of 
5–9 animals per group. *P < 0.05, **P < 0.01 
(Student’s t test). (B) Plasma concentration of 
IL-6. Results represent mean ± SEM of 5 ani-
mals per group. *P < 0.05 (Student’s t test).
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tration, macrophages adhered more readily to 3T3-L1 adipocytes 
stimulated with FasL (Figure 7B). Thus, adipocyte Fas plays a role 
in modulating adipose tissue inflammatory response to obesity.
What is the mechanism for increased adipocyte Fas expression 
in obesity? We observed that Fas expression was higher in larg-
er compared with smaller adipocytes isolated from the same fat 
depot of HFD-fed WT mice (Supplemental Figure 9). Yet given 
that adipocyte size in AFasKO mice on HFD was comparable to 
that in controls, it is unlikely that the increased adipose tissue Fas 
expression is the consequence of higher abundance of hypertro-
phied adipocytes in this mouse model. Rather, studies in 3T3-L1 
adipocytes suggest that TNF-α and IL-1β, two key proinflamma-
tory cytokines arising early in the inflammatory process, induce 
Fas expression (see Supplemental Figure 10). Moreover, at later 
stages of adipose tissue inflammation, adipose tissue is infiltrated 
by inflammatory cells, such as T cells and macrophages, which 
express and secrete FasL (10). Intriguingly, we found Fasl mRNA 
to be upregulated in WAT of ob/ob mice (Figure 1C). Thus, it is very 
likely that the trigger to upregulate Fas expression and activation 
in adipose tissue in obesity is the increased production of proin-
flammatory cytokines and FasL. Intriguingly, a similar regulation 
was previously shown for TNF, i.e., expression of TNF receptor 
was shown to be upregulated by different cytokines as well as by 
TNF (31, 32). Thus, like many other inflammatory mediators that 
participate in feed-forward loops to enhance the inflammatory 
response, Fas appears to be both the target and a positive mediator 
of the proinflammatory cascade of adipose tissue in obesity.
Enhanced Fas expression and activation in adipose tissue have 
functional consequences at the level of both adipose tissue and, 
indirectly, the liver. Fas is well characterized as a proapoptotic fac-
tor, and adipocyte hypertrophy in obesity was proposed to pro-
mote adipocyte cell death, possibly with some apoptotic charac-
teristics (33). It is therefore conceivable that enhanced adipocyte 
Fas expression sensitizes adipocytes to FasL-induced apoptosis. 
In addition, Fas activation may exert direct metabolic/endocrine 
effects unrelated to cell death, reminiscent of the metabolic/endo-
crine effects of TNF-α (34).
Adipose tissue inflammation was pre-
viously correlated with hepatic steatosis 
(26). Consistent with this finding, abla-
tion  of  Fas  specifically  in  adipocytes 
was associated with decreased hepatic 
steatosis and hepatic insulin resistance 
(Figures 8 and 9). Moreover, cultured 
medium from FasL-treated 3T3-L1 adi-
pocytes  induced  insulin  resistance  in 
cultured hepatocytes (Figure 9C), sup-
porting a potential  role of adipocyte-
expressed Fas in the induction of per-
turbed adipocyte-hepatocyte crosstalk 
that results in hepatic insulin resistance. 
A possible candidate mediating the link 
between adipose  tissue  inflammation 
and  hepatic  steatosis/insulin  resis-
tance is IL-6. Indeed, IL-6 treatment of 
hepatocytes induced insulin resistance 
in vitro (35), and it seems to be gener-
ally accepted that  IL-6 causes hepatic 
insulin resistance (24). Particularly, IL-6 
was shown to induce phosphorylation 
of IRS1 on Ser307 residue and to activate the negative insulin 
signaling regulator SOCS3 in C57BL/6J mice (36, 37). Accord-
ingly, IL-6 expression in adipose tissue and circulating IL-6 levels 
were reduced in HFD-fed AFasKO mice, and their livers exhibited 
decreased Ser307 phosphorylation of IRS1 and decreased mRNA 
levels of Socs3 compared with those of WT mice.
Besides IL-6, elevated portal delivery of FFAs or resistin may lead 
to hepatic steatosis and/or hepatic insulin resistance in rodents (38, 
39). Of note, insulin-induced inhibition of lipolysis was maintained 
in AFasKO but not in HFD-fed WT mice (in vivo and in vitro), sug-
gesting that postprandial hyperlipidemia could be prevented by 
adipocyte-specific Fas deletion. Likewise, mRNA levels of the fatty 
acid transporter Cd36 were significantly increased in livers of HFD-
fed WT mice, suggesting increased hepatic fatty acid uptake (40). 
In turn, increased delivery of FFAs to the liver might contribute to 
higher ceramide levels in WT compared with AFasKO livers (Figure 
8B) and subsequently to hepatic insulin resistance (41). Moreover, 
hepatic glucose production was lower in HFD-fed AFasKO mice 
(as assessed by hepatic glucose production during clamp studies). 
Interestingly, mRNA expression levels of gluconeogenic enzymes 
were not different in AFasKO and WT mice. This apparent contra-
diction might be due to the fact that liver samples were obtained 
in randomly fed mice. Moreover, similar findings with differences 
in gluconeogenic flux but without differences in mRNA levels of 
Pck1 and G6pc were previously reported by others (42). In addition, 
expression levels of PEPCK and G6Pase may not always accurately 
reflect gluconeogenesis flux (43, 44). Thus, adipocyte-specific Fas 
deletion protects the liver from developing insulin resistance and 
hepatic steatosis by interfering with Fas-mediated adipose tissue 
inflammation and/or metabolic dysregulation.
The relevance of our studies to human obesity are suggested by our 
finding that Fas is upregulated in adipose tissue of obese patients and 
even more so in obese diabetic patients. This finding may hint at a 
role of Fas in the development of obesity-induced insulin resistance in 
humans. Intriguingly, recent studies in humans revealed an associa-
tion of promoter alterations in the Fas and FasL gene with type 2 dia-
betes and insulin resistance (45), further supporting such a notion.
Figure 7
Increased secretion of immunoattractant cytokines and higher macrophage adherence in FasL-
treated 3T3-L1 adipocytes. (A) Fas ligation increases expression of proinflammatory cytokines 
in 3T3-L1 adipocytes. Mature 3T3-L1 adipocytes were incubated in the presence or absence 
of 2 ng/ml FasL for 12 hours. Medium was removed, and cells were incubated with KREBS 
buffer. Cytokine levels were then determined in the supernatant. Shown are results normalized 
to untreated cells. Results represent mean ± SEM of 4–5 independent experiments. *P < 0.05 
(1-sample t test). (B) Mature 3T3-L1 adipocytes were incubated in the presence or absence 
(control [Co]) of 2 ng/ml FasL for 12 hours. Thereafter, adipocytes were incubated with 3H-labeled 
macrophages for 1 hour at 37°C. Cells were washed and lysed (0.05N NaOH). Finally, radioactiv-
ity of lysates was determined by a beta counter. Results represent mean ± SEM of 7 independent 
experiments. *P < 0.05 (1-sample t test).
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In conclusion, our findings suggest that Fas activation in adi-
pocytes contributes to the increased production and secretion 
of inflammatory cytokines in obesity and thus contributes to 
the development of insulin resistance. Based on these findings, 
it would seem important to determine whether inhibition of 
Fas expression/activation in adipocytes constitutes a potential 
new therapeutic target in the treatment of insulin resistance and 
type 2 diabetes.
Methods
Human samples. Fat biopsy samples were taken from women undergoing 
elective laparoscopic abdominal surgery at the Soroka University Medical 
Figure 8
Reduced hepatic steatosis in HFD-fed AFasKO mice. (A) H&E-stained liver sections from WT (Fasfl/fl;Fabp4-Cre–/–) and AFasKO (Fasfl/fl;Fabp4-
Cre+/–) mice (original magnification, ×40). Total liver lipids were determined and expressed relative to lipid content in WT mice. Results repre-
sent mean ± SEM of 8 mice of each group. *P < 0.05 (Student’s t test). (B) Levels of detected liver ceramide species are shown. Results are 
mean ± SEM of 6–8 animals per group and are expressed relative to total lipids in WT mice. *P < 0.05 (Student’s t test). n.d., not detected. (C) 
mRNA expression of indicated markers in liver tissue of WT and AFasKO mice was analyzed. Results are mean ± SEM of 5–9 mice per group, 
expressed relative to WT and normalized to expression of 18S. *P < 0.05 (Student’s t test). (D and E) Liver lysates were prepared from WT and 
AFasKO mice and resolved by LDS-PAGE. (D) Lysates were immunoblotted with ADRP, PPARγ, or actin antibodies. Results are mean ± SEM 
of 4–6 animals per group and expressed relative to protein expression in WT mice. *P < 0.05 (Student’s t test). (E) Lysates were immunoblotted 
with anti–phospho–p65 NF-κB or anti-actin antibody. Expression levels of phospho-p65 are normalized to expression of actin. Results are 
mean ± SEM of 5–6 mice and expressed relative to WT.
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Center (Beer-Sheva, Israel) as described and characterized elsewhere (46, 
47). All procedures were approved in advance by the Soroka University 
Medical Center Institutional Review Committee. Patients gave written 
informed consent for all procedures.
Animals. C57BL/6J WT and Fas-def mice backcrossed for more than 
10 generations onto this same C57BL/6J inbred strain background (B6.
MRLlpr) were obtained from The Jackson Laboratory. Mice with exon 9 
of Fas flanked with loxP sites were produced as described previously (48). 
Animals with Cre recombinase controlled by the Fabp4 promoter [B6.Cg-
Tg(Fabp4-cre)1Rev/J] were purchased from The Jackson Laboratory. All 
mice were genotyped by PCR with primers amplifying the Cre transgene and 
Fas, generating 319-bp WT and 399-bp floxed allele products. C57BL/6J 
WT (C57BL/6JOlaHsd), ob/ob  (C57BL/6OlaHsd-Lep<ob>), and db/db 
(BKS.Cg-+Leprdb/+Leprdb/OlaHsd) mice were purchased from Harlan.
All mice were housed in a specific pathogen–free environment on a 12-hour 
light/12-hour dark cycle and fed ad libitum a regular chow diet (Provimi 
Kliba) or HFD (58 kcal% fat with sucrose Surwit Diet, D12331, Research 
Diets). All protocols conformed to Swiss animal protection laws and were 
approved by the Cantonal Veterinary Office (Zurich, Switzerland).
Harvesting of naive splenic macrophages. Splenocytes were isolated in PBS 
by smashing the spleen through a metal grid with a syringe plunger. After 
removal of residual tissue, cells were washed and resuspended in 0.4 ml 
MACS buffer (1× PBS, 2% FCS, 5 mM EDTA). Twenty microliters of appro-
priate beads (anti-CD11b; Miltenyi Biotec) was added, and the suspension 
was incubated on ice for 15 minutes. Upon washing, cells were applied to 
the MACS magnetic separator according to the manufacturer’s protocol. 
To elute the appropriate cells, MACS buffer was pushed through the col-
umn with a plunger. For FACS analysis (before and after MACS), about 
3 × 106 splenocytes were resuspended in FACS buffer (1× PBS, 2% FCS, 0.2% 
sodium azide, 0.02 M EDTA) and stained with anti-CD11b–PE (BD Biosci-
ences — Pharmingen) labeled antibody. After washing of the cells with FACS 
buffer, cells were analyzed immediately using FlowJo software (Tree Star).
Induction of activated peritoneal macrophages by thioglycollate. Three months 
before use, 30 g thioglycollate medium (Difco, Chemie Brunschwig AG) 
was rehydrated in 1 l H2O and autoclaved. For induction of activated peri-
toneal macrophages, mice were injected i.p. with 1 ml thioglycollate sus-
pension. Seventy-two hours later, the mice were sacrificed, and the perito-
neum was flushed with cold PBS in order to harvest the macrophages.
Intraperitoneal glucose, insulin, and pyruvate tolerance tests. For the intraperitoneal 
glucose tolerance test mice were fasted overnight; for the intraperitoneal insu-
lin and pyruvate tolerance tests, mice were fasted for 3 hours. Glucose (2 g/kg 
body weight), human recombinant insulin (0.75 U/kg or 1 U/kg body weight), 
or pyruvate (2 g/kg body weight) was injected intraperitoneally (49).
Glucose incorporation into isolated white adipocytes. Adipocyte isolation was 
performed as described previously (21, 50). To determine glucose incor-
poration, adipocytes were incubated with d-[U-14C]glucose (final glucose 
concentration, 0.89 mmol/l) for 60 minutes in the presence or absence of 
100 nM insulin. Glucose incorporation was stopped by separating cells 
from the medium by centrifugation through phthalic acid dinonyl ester 
and then subjecting them to liquid scintillation counting.
Adipocyte size determination. Aliquots of adipocyte fractions were used to 
determine mean cell diameters. Photographs of isolated adipocytes in the 
hemocytometer were taken, and images were analyzed using NIH ImageJ 
software for quantification (http://rsbweb.nih.gov/ij/). At least 100 adipo-
cytes per mouse were analyzed.
Determination of plasma insulin, adipokine, FFA, TG, and glycerol levels. Plasma 
insulin and FFA levels were determined as described previously (49). Plas-
ma adipokine and cytokine levels were determined with mouse LINCOplex 
kits from Linco Research Inc. (Labodia). TG and glycerol concentrations 
were determined using a colorimetric assay (Sigma-Aldrich).
Figure 9
Improved hepatic insulin sensitivity in AFasKO mice. (A) Lysates were immunoblotted with anti–phospho-IRS1 (Ser307) and total IRS1 antibody. 
Expression levels of pSer307 are normalized to expression of total IRS1. Results are mean ± SEM of 4 mice and expressed relative to WT. *P < 0.05 
(Student’s t test). (B) Hepatic glucose production was calculated in the basal period and in response to insulin infusion during the hyperinsulinemic-
euglycemic clamp study. Results are mean ± SEM of 3–4 animals per group and expressed relative to basal hepatic glucose production. **P < 0.01 
(Student’s t test). (C) 3T3-L1 adipocytes were incubated with or without FasL for 12 hours, and subsequently, supernatant was collected for 24 hours. 
Hepatoma cells (Fao) were incubated with the conditioned medium for 24 hours. Total cell lysates were prepared and resolved by LDS-PAGE and 
immunoblotted with anti–phospho-Akt or Akt antibody. Results are mean ± SEM of 7–9 independent experiments. **P < 0.01 (ANOVA).
research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 1      January 2010  201
Total liver lipid extraction. Liver tissue (30 mg) was homogenized in PBS, 
and lipids were extracted in a chloroform/methanol (2:1) mixture. Total 
liver lipids were determined by a sulfo-phospho-vanillin reaction as previ-
ously described (51).
Ceramide and diacylglycerol analysis in liver tissue. Extraction of lipids from 
liver tissue (30 mg) was performed by the method of Bligh and Dyer (52) 
with 50 mM potassium phosphate buffer in the aqueous layer and β-sitos-
terol (2 μg; Sigma-Aldrich) as internal standard. Lipid extracts were ana-
lyzed on a Q-TOF Ultima spectrometer (Waters) equipped with a NanoMate 
HD (Adrion Biosciences Ltd.) by direct infusion of the samples. Ammoni-
um acetate (final concentration, 7.5 mM) was added to the extracts prior to 
analysis to induce ionization. Data were analyzed using MassLynx (version 
4.1, Waters), and targeted lipids were identified based on their exact mass. 
Relative quantities of all lipids were reported as background corrected 
intensity ratios relative to the internal standard β-sitosterol.
RNA extraction and quantitative RT-PCR. Total RNA from fat pads was 
extracted with the RNeasy Lipid Tissue Mini Kit (QIAGEN) and analyzed 
with a Bioanalyzer (Agilent Technologies). RNA (0.75 μg) was reverse tran-
scribed with Superscript III Reverse Transcriptase (Invitrogen) using random 
hexamer primer (Invitrogen). TaqMan system (Applied Biosystems) was used 
for real-time PCR amplification. Relative gene expression was obtained after 
normalization to 18s RNA (Applied Biosystems), using the formula 2–ΔΔcp 
(53). The following primers were used: TNF-α, Mm00443258_m1; IL-6, 
Mm00446190_m1; KC, Mm00433859_m1; IL-1β, Mm0043422/8_m1; FasL, 
Mm00438864_m1; cd11b, Mm00434455_m1; MCP-1, Mm00441242_m1; 
resistin, Mm00445641_m1; SOCS3, Mm00545913_s1; CD36, Mm00432403_
m1;  ArgI, Mm00475988_m1;  IL-10, Mm00439614_m1;  adiponectin, 
Mm00456425_m1; PPARγ, Mm00440945_m1; PEPCK, Mm0044636_
m1;  G6Pase,  Mm00839363_m1;  FAS,  Mm00662319_m1;  ACC-1, 
Mm01304289_m1; SCD-1, Mm01197142_m1; CPT-1, Mm00550438_m1; 
PPARα, Mm00627559_m1; AOX, Mm00443579_m1 (Applied Biosystems).
Glucose clamp studies. Glucose turnover rate was assessed in freely moving 
mice after 6 weeks of HFD during a euglycemic-hyperinsulinemic clamp. 
Briefly, mice were anesthetized with isoflurane, and a catheter (MRE 025, 
Braintree Scientific) was inserted into the left jugular vein and exteriorized 
at the back of the neck. After 7 days of recovery, only mice that had regained 
greater than 95% of their preoperative weight were studied. After a fasting 
period of 5 hours, 3-[3H]glucose (0.1 μCi/min; PerkinElmer) was infused for 
80 minutes, and blood was collected from tail tip for basal turnover calcula-
tion. After basal sampling, insulin (18 mU/kg/min) was infused for 2 hours. 
Euglycemia was maintained by periodically adjusting a variable infusion of 
20% glucose with a syringe pump (TSE Systems). The glucose infusion rate 
was calculated as the mean of the steady-state infusion (60–90 minutes) after 
1 hour of insulin infusion. A blood sample was collected from tail tip after 
steady-state infusion. The glucose turnover rate was calculated by dividing 
the rate of 3-[3H]glucose infusion by the plasma 3-[3H]glucose–specific activ-
ity. Hepatic glucose production was calculated by subtracting the glucose 
infusion rate from the glucose turnover rate.
Western blot analysis. Cell lysates and tissue samples were homogenized in 
a buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 
1% NP-40, 0.25% sodium deoxycholate, 1 mM sodium vanadate, 1 mM NaF, 
10 mM sodium β-glycerophosphate, 100 nM okadaic acid, 0.2 mM PMSF, 
and a 1:1,000 dilution protease inhibitor cocktail (Sigma-Aldrich). For isola-
tion of total membranes, 3T3-L1 adipocytes were lysed and homogenized 
in a buffer containing 20 mM HEPES, 250 mM sucrose, 5 mM NaN3, 1 mM 
EDTA, 0.2 mM PMSF, and a 1:1,000 dilution protease inhibitor cocktail. 
Lysates were centrifuged at 229,000 g for 90 minutes at 4°C, and the pellet 
was resuspended in homogenization buffer.
Protein concentration was determined using BCA assay (Pierce), and 
equivalent amounts of protein (20–50 μg) were resolved by LDS-PAGE 
(4%–12% gel; NuPAGE, Invitrogen). Proteins were transferred to a nitrocel-
lulose membrane (0.2 μm; Bio-Rad) and blocked for 1 hour in 5% nonfat 
dry milk (Bio-Rad) resolved in Tris-buffered saline, containing 1% Tween-
20. Membranes were incubated overnight at 4°C on a rocking platform 
with respective primary antibodies. The following primary antibodies were 
used: anti-GLUT4 (gift of A. Klip, The Hospital for Sick Children, Toronto, 
Ontario, Canada), anti-Fas, anti–phospho-IRS1 (Ser307) (Upstate), anti-
Fas (human), anti-IRS1, anti-PPARγ, anti-C/EBPα and anti-C/EBPβ (Santa 
Cruz Biotechnology Inc.), anti-ADRP (Novus Biologicals), anti-Cre and 
anti-actin (Millipore), anti–phospho-Akt (Ser473), anti-Akt and anti–phos-
pho–NF-κB p65 (Cell Signaling Technology). Subsequently, membranes 
were incubated with secondary antibody (HRP-conjugated; Santa Cruz 
Biotechnology and Alexis Biochemicals) for 1 hour at room temperature. 
Bands were detected after 5-minute incubation with Lumi-Light substrate 
(Roche). Membranes were exposed in an Image Reader and analyzed with 
Image Analyzer (FujiFilm).
Determination of 2-deoxy-3H-d-glucose uptake and lipolysis in 3T3-L1 cells. 3T3-
L1 cells were grown and differentiated into adipocytes as described pre-
viously (50). Uptake and lipolysis of 2-deoxy-3H-d-glucose (3H-2dG) were 
measured in mature 3T3-L1 adipocytes as previously reported (50, 54).
Macrophage adherence assay. Thioglycollate-activated macrophages (as 
described above) were labeled with 3H-2dG (55) by incubation with HEPES-
buffered saline containing 2.5 mM d-glucose and 5 μCi/ml 3H-2dG for 
1 hour at 37°C. Glucose uptake was stopped by 2 washes with cold HEPES-
buffered saline. Labeled macrophages were resuspended in HEPES-buffered 
saline and added to mature 3T3-L1 adipocytes, treated with or without 
2 ng/ml FasL for 12 hours in advance. After 1 hour of incubation at 37°C, 
cells were washed and lysed (0.05N NaOH). Finally, radioactivity of lysates 
was determined by a beta counter.
Experiments with conditioned medium. Mature 3T3-L1 adipocytes were incu-
bated without or with 2 ng/ml FasL for 12 hours. Cells were rinsed with PBS, 
and fresh medium (DMEM) was added and collected after 24 hours. There-
after, hepatoma cells (Fao) were incubated for 24 hours with conditioned 
medium from untreated or FasL-treated adipocytes. Fao cells were rinsed 
and stimulated with insulin (100 nM) for 7 minutes. Lysates were prepared 
and subjected to Western blot analysis using respective antibodies.
Statistics. Data are presented as mean ± SEM and were analyzed by 2-tailed 
Student’s t test, 1-sample t test, or ANOVA with a Tukey correction for mul-
tiple group comparisons. P values less than 0.05 were considered significant.
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